“What have you been reading?”

Most of the time, I get the same answer.

“I’ve been on Google.”

Just days after hearing the words “you have prostate cancer,” most men are faced with a flood of information. One website says to have surgery right away. Another suggests radiation. Someone else warns that active surveillance is risky. Soon, all these opinions start to conflict, and fear can take over.

I get why this happens. The word “cancer” is heavy and emotional. It makes everything feel urgent, even when there may be time to pause.

I always tell men that prostate cancer is not like many other cancers. Often, it grows slowly. This doesn’t mean you should ignore it, but it does mean you usually have time to learn about your diagnosis and think carefully before choosing treatments that could affect things like urinary or sexual health, energy, and your overall quality of life.

I made a whole podcast episode about this because I think too many men feel pressured to make quick decisions before they really know what’s going on. If you haven’t heard it yet, try starting with “The Overdiagnosis Trap: Why Common Prostate Screenings Often Lead to Unnecessary Harm.” This episode explains why it’s important to learn first, then act.

Reading can help in the same way.

Books aren’t a substitute for doctors, and they shouldn’t be. But they do give you time. Reading lets you step back from the stress and learn about the science, the history, and the important questions you should ask before making a decision.

That’s why I suggest these five books.

The Great Prostate Hoax

Richard Ablin discovered prostate-specific antigen, but later became a strong critic of how PSA was used as a screening test for everyone. You might not agree with all his conclusions, but his book gives important background on how PSA screening became common and why it’s still debated in men’s health.

If you started this journey with a high PSA, I also suggest my podcast, “Prostate-Specific Antigen (PSA) Test. Should You Get One?” It covers many of the same questions about what PSA really means.

Fight Cancer Like a Man

I wrote Fight Cancer Like a Man after seeing too many men think they only had one choice.

Again and again, I saw men go straight from a high PSA to a biopsy, surgery, or radiation, without enough talk about long-term results, quality of life, or whether these treatments would really help them in the future.

This book isn’t about ignoring prostate cancer. It’s about understanding it. It’s also about realizing that keeping your strength, energy, and independence is just as important as treating the disease.

If you’ve seen my episode “Say NO to Prostate Cancer Biopsies, Surgery, and Radiation,” you’ll notice many of the same ideas are discussed in more detail in the book.

Testosterone for Life

Hormones are still one of the most misunderstood parts of men’s health.

For years, men have been told to be afraid of testosterone, especially after being diagnosed with prostate cancer. But testosterone does much more than affect sexual function. It also impacts muscle, bones, metabolism, heart health, thinking, and overall resilience.

Dr. Abraham Morgentaler’s work changed how we talk about this, and I think every man should know how hormones affect healthy aging.

If you’re interested in this topic, check out my podcast, “Erectile Dysfunction After Prostate Cancer | Testosterone, TRT, and Peyronie’s Explained.”

The Structure of Scientific Revolutions

This book isn’t about prostate cancer, and that’s exactly why I included it.

Thomas Kuhn explains how science changes over time. New discoveries don’t usually replace old ideas right away. Medicine often holds on to old ways until the proof is too strong to ignore.

Knowing how this works helps explain why there are still debates about PSA, biopsies, hormone therapy, and prostate cancer treatments. It shows that asking questions about accepted ideas isn’t against science—it’s how science moves forward.

Lifespan

One of the biggest mistakes in healthcare is treating diseases as if they are separate from the rest of the body.

Your prostate is affected by your metabolism, which in turn is shaped by things like what you eat, how much you exercise, your sleep, body makeup, inflammation, hormones, and many other factors.

Dr. David Sinclair’s Lifespan asks readers to look beyond just treating disease and focus on keeping healthy in the first place. You might not agree with everything, but I strongly support his main point: healthy aging starts well before any illness appears.

If you’ve listened to my podcast before, you’ll know I talk about this idea a lot. Episodes like “Nutrition and Prostate Cancer,” “The Best Exercise for Prostate Cancer,” and “Why ‘Cancer Free’ May Be Giving Patients False Confidence” all look at ways to build a healthier body from the inside out.

The Value of Reading

I don’t expect everyone to agree with all the authors here. In fact, disagreeing is part of how we learn.

The goal isn’t just to find opinions that match what you already think. It’s to understand the facts, appreciate different views, and feel confident asking better questions.

Getting diagnosed with prostate cancer changes your life, but it shouldn’t push you into quick decisions made out of fear. Most of the time, you have time to learn, think, get more opinions, and choose what fits your goals and values.

The best medical choices usually aren’t made in a rush. They come from understanding, patience, and asking the right questions before you decide.

That’s why I suggest reading first and giving yourself time to understand your options before making a decision.

Start With Understanding

Before you agree to a biopsy. Before you schedule surgery. Before you begin radiation or hormone therapy.

Take the time to understand what you’re facing.

Fight Cancer Like a Man was written to help men slow down, ask better questions, understand the science behind prostate cancer, and make thoughtful decisions based on evidence rather than fear.

Your diagnosis is only the beginning of the conversation. Make sure you’re equipped with the knowledge to take part in it.

Get your copy of Fight Cancer Like a Man today.

Dr. Stephen Petteruti is a board-certified physician specializing in longevity-focused, integrative medicine. He works with men navigating prostate cancer, testosterone and hormone health, aging, and performance using proactive, evidence-informed strategies grounded in real clinical practice.

Learn more at www.intellectualmedicine.com and www.drstephenpetteruti.com

Follow Dr. Petteruti on Instagram and Facebook: @intellectualmedicine

The content in this article reflects the opinions and clinical experience of Dr. Stephen Petteruti and is intended for informational and educational purposes only. It is not medical advice and should not replace guidance from your personal healthcare provider. Always consult your physician before making changes to your health regimen.

Too many men are making life-changing health decisions without having access to the information they deserve. My goal is to help men ask better questions, understand their options, and take control of their health.

If you’ve found value in these articles, I’d appreciate your help in reaching more men.

I’ve created a referral program to thank readers who share this newsletter with friends, family, and colleagues.

Here’s how it works

1. Share your personal referral link.

Use the link below or click the Share button on any article. Every time someone subscribes using your link, your referral count increases.

Refer a friend

2. Earn exclusive rewards.

As more people subscribe through your link, you’ll unlock special thank-you gifts.

5 Referrals
📘 Prostate Survival Toolkit

Practical downloads to help you better understand prostate health, track your progress, and prepare for medical appointments.

15 Referrals
📖 Signed Copy of Fight Cancer Like a Man

A personally signed copy of my book sharing the philosophy that has guided my approach to prostate cancer and men’s health.

30 Referrals
🏆 One-Year Membership to the Men’s Vitality Community

Join our private community for exclusive educational content, resources, discussions, and live events focused on helping men live healthier, stronger lives.

Visit the leaderboard

Every person you refer helps us reach another man who may be looking for answers.

Thank you for being part of this community and for helping us spread a message that puts education, critical thinking, and better health first.

Dr. Stephen Petteruti

“Something isn’t the way it used to be.”

Maybe erections aren’t as firm. Maybe desire isn’t what it was five or ten years ago. Maybe energy is fading, or confidence has taken a hit. Most men don’t bring it up right away. They wait, hope it gets better, and sometimes convince themselves it’s simply part of getting older. But I don’t accept that answer.

Sexual performance isn’t just about what happens in the bedroom. It’s one of the earliest windows into a man’s overall health. When sexual function begins to change, I want to know why. Too often, it’s the first sign that something else has been developing below the surface for years. That’s why I don’t dismiss it.

Unfortunately, many men never get that conversation. They leave the doctor’s office with a prescription for Viagra or Cialis, and that’s where the discussion ends. Those medications certainly have a place, and for many men, they improve erections. But they don’t explain why the problem developed in the first place. If we stop there, we’ve treated a symptom while overlooking the cause.

An erection is surprisingly complicated. Healthy blood vessels, good circulation, balanced hormones, normal nerve function, proper metabolism, and even sleep all have to work together. When one of those systems begins to struggle, sexual performance is often one of the first things to change.

That’s why erectile dysfunction gets my attention.

The arteries supplying the penis are much smaller than the arteries supplying the heart. When blood flow begins to decline, the penis often notices before the heart does. I’ve seen men come in worried about their sexual performance only to discover they have insulin resistance, poorly controlled blood sugar, high blood pressure, low testosterone, sleep apnea, or significant inflammation. The erection wasn’t the problem. It was the warning light on the dashboard, and that’s why I paid attention.

Testosterone is another area where I think we oversimplify the conversation. Every week, someone asks whether they simply need more testosterone. Sometimes the answer is yes. Many times it isn’t.

I’ve seen men whose testosterone was low because they were carrying excess body fat, sleeping poorly, living under constant stress, or struggling with metabolic disease. If we never ask why testosterone declined, we’re treating a laboratory value instead of the patient.

Obesity and insulin resistance play a much larger role than most people realize. Excess body fat changes hormone balance. Blood sugar problems increase inflammation and damage blood vessels. Over time, circulation suffers, testosterone falls, energy disappears, muscle is lost, and sexual performance begins to decline. None of those problems exist in isolation. They’re connected.

This is one reason I spend so much time talking about metabolic health. Men often think they’re asking me about erectile dysfunction when, in reality, they’re asking about their cardiovascular health, hormone balance, body composition, and future risk for chronic disease. Sexual performance is simply the first symptom they noticed, which is why the bigger picture matters.

That also explains why my recommendations don’t always begin with another prescription. Yes, medications have a role. So does testosterone replacement when it’s appropriate. But I’ve watched men dramatically improve their sexual performance after losing body fat, building muscle, boosting insulin sensitivity, sleeping better, correcting nutritional deficiencies, and getting inflammation under control. Those changes don’t just improve erections. They improve health, and that’s the point.

At the end of the day, I’m far less interested in helping a man perform better for one night than I am in helping him stay healthy for the next twenty years. Sexual performance is part of that conversation, but it isn’t the destination. It’s often one of the clearest indicators of what’s happening throughout the rest of the body, and that is why I pay attention to it.

Subscribe now

If you’ve noticed changes, don’t ignore them, and don’t assume it’s simply because you’re getting older. Ask why now. Talk to your doctor and find out what’s driving the problem. Your body may be telling you something long before a more serious disease develops. The sooner you understand what’s driving the problem, the more opportunities you have to correct it. That’s how you protect not only your sexual health but your total vitality and quality of life.

If this topic resonates with you, I've written a more in-depth article that explores the relationship between sexual performance, testosterone, blood flow, metabolic health, and the lifestyle factors that influence them. I discuss why erectile dysfunction is often a symptom rather than the underlying problem and the questions every man should ask before simply reaching for a prescription. You can read the full article, Male Sexual Performance: How to Improve Confidence, Energy, and Performance, on my website.

On the surface, that sounds reasonable. But I believe this is one of the most misunderstood and under-questioned areas in prostate cancer care.

After decades of studying prostate cancer and helping men navigate these decisions, I have reached a conclusion that many find uncomfortable but necessary to discuss openly. Radiation causes guaranteed harm in exchange for uncertain benefit.

Too often, radiation is presented as though it is a safe and obvious next step. The problem is that this framing ignores the long-term consequences and often overstates the benefit.

What Radiation Actually Does

The first thing every man needs to understand is that radiation does not remove the prostate. It damages tissue in an attempt to destroy cancer cells. Radiation affects not only the prostate but also surrounding structures, including the bladder, rectum, blood vessels, and nerves responsible for urinary and sexual function. In other words, the treatment itself creates collateral damage.

This becomes important when you consider the nature of prostate cancer. Most prostate cancers are slow growing. Many men diagnosed with prostate cancer will never die from it. Yet countless men undergo irreversible treatment for a disease that may never have shortened their life in the first place.

If the disease may never harm you, why rush into a treatment that definitely will?

What the Research Shows

One of the landmark studies in prostate cancer, the ProtecT trial, compared surgery, radiation, and active monitoring. The results were striking. There was no meaningful survival advantage from aggressive treatment compared to observation alone in localized prostate cancer.

A treatment with permanent side effects failed to show a meaningful survival benefit over simply monitoring the disease.

The issue is not whether radiation can affect cancer cells. The issue is whether it improves meaningful outcomes enough to justify what is lost in the process. That is a very different question, and it is the question too few men are encouraged to ask.

Subscribe now

The Side Effects Men Need to Understand

The side effects of radiation are often minimized during the decision-making process. Urinary incontinence, erectile dysfunction, bowel dysfunction, chronic fatigue, rectal irritation, and sexual dysfunction are all well-documented consequences. Some complications appear immediately. Others take years to develop. In some men, damage continues to evolve long after treatment ends.

Radiation also carries another risk that deserves more attention. Radiation itself can increase the risk of secondary cancers later in life. That is not something most men fully appreciate when they are first told radiation is their best option.

The Problem Few Men Are Told About

Radiation does not guarantee the cancer is gone. Many men experience biochemical recurrence after radiation. PSA begins rising again. In simple terms, the cancer was not eliminated or has resumed activity. When that happens, the situation becomes far more complicated.

Once tissue has been irradiated, treatment options narrow significantly. Additional radiation becomes difficult or impossible. Surgery on a previously irradiated prostate is far more complicated and carries higher risk. Tissue becomes scarred, damaged, and less forgiving.

This means one of the biggest costs of radiation is not just what happens immediately. It is the fact that it can eliminate options you may wish you still had later.

What About HIFU, NanoKnife, and Focal Therapy?

This same concern applies to newer focal treatments being marketed as safer alternatives. HIFU, NanoKnife, focal radiation, and similar technologies are often promoted as more precise and less harmful. I remain cautious.

Why? Because the central issue has not changed.

The question is not whether we have newer tools. The question is whether treatment is truly necessary in the first place. If we are aggressively treating slow-growing disease that may never cause meaningful harm, then the technology itself does not solve the underlying problem.

Even highly targeted treatment remains treatment. And treatment always carries tradeoffs.

Even Advanced Radiation Has Tradeoffs

Even in advanced disease, these tradeoffs matter. Consider PLUVICTO, a radiation-based treatment for metastatic prostate cancer. It has received substantial attention as a newer therapy. PLUVICTO extended life by approximately four months at a cost exceeding $250,000. More than half of patients experienced severe adverse events. Patients must also isolate from family members after each treatment for 7 days because of radiation exposure.

A meaningful portion of the limited survival benefit may be spent managing side effects or living in isolation.

If a treatment extends life by four months on paper, but a third of that time is spent isolated, recovering, managing side effects, and feeling unwell, we have to ask a much more important question. What kind of life extension are we really talking about?

Subscribe now

My Philosophy on Radiation

My philosophy on radiation is simple. The goal should never be treatment for the sake of treatment. The goal should be preserving both longevity and quality of life.

Radiation, like surgery, is irreversible. Once it is done, it cannot be undone. The damage to surrounding tissue is permanent. That is why I do not recommend radiation for prostate cancer. This is not because I dismiss cancer or ignore risk. It is because I believe men deserve thoughtful decisions based on the full clinical picture, not automatic treatment pathways driven by fear and urgency.

The Real Problem Is Fear

That brings us to what I believe is the biggest problem in prostate cancer care: fear.

The word cancer creates fear. Fear creates urgency. Urgency drives rushed decisions. That is where mistakes happen. Prostate cancer is rarely a true medical emergency. Most men have time. Time to gather information. Time to ask harder questions. Time to understand the risks, benefits, and long-term consequences of every option.

Because the decision you make today may affect your strength, vitality, urinary function, sexual health, and independence for years to come.

Final Thoughts

If a man chooses radiation after fully understanding the evidence, risks, and tradeoffs, I respect that decision. But it must be a deliberate decision. It should never be a reflexive response to fear, pressure, or blind trust in protocol.

You only get one body. You only get one life.

Choose carefully.

As honest as that is, many people, even oncologists, find it difficult to believe.

For decades, men have been taught that finding prostate cancer early is one of the most important steps they can take to protect their health. The logic appears obvious: detect cancer as soon as possible, treat it quickly, and improve the chances of survival.

For some cancers, that approach has often saved lives.

Prostate cancer, however, presents a more complicated picture. Research has shown that many men develop abnormal prostate cells as they age, yet a substantial number of those abnormalities never progress into life-threatening disease. Some grow very slowly. Others may never cause symptoms at all.

This creates an uncomfortable question: If some prostate cancers would never have caused harm, what happens when we find them anyway?

The answer lies at the heart of one of the most debated topics in modern medicine: overdiagnosis.

For years, the conversation around prostate cancer has focused on finding more disease. Increasingly, however, researchers and physicians are asking a different question. Are we always helping patients when we find abnormalities, or are some men being exposed to unnecessary anxiety, procedures, and treatments that may never have improved their outcomes in the first place?

The answer is not as simple as supporters or critics of screening often suggest.

Why Prostate Cancer Is Different

The challenge begins with a reality that makes prostate cancer unlike many other cancers.

Most patients do not care whether abnormal cells exist inside their prostate. What they care about is whether those cells will threaten their health, shorten their lives, or reduce their quality of life. Unfortunately, those are not always the same question.

Finding cancer cells is relatively easy compared to predicting what those cells will do over the next ten or twenty years.

This distinction is often overlooked in public discussions about screening. The assumption is that every cancer diagnosis represents a dangerous disease that requires immediate attention. Yet decades of research have shown that prostate cancer exists on a wide spectrum. Some tumors are aggressive and require treatment. Others may remain stable for years without causing significant harm.

Dr. Petteruti has explored this issue in several discussions, including Do Men Really Die From Prostate Cancer? What the Data Actually Shows. A recurring theme in that conversation is the distinction between identifying abnormal cells and identifying a life-threatening disease. While those concepts are often treated as interchangeable, they are not necessarily the same thing.

That difference shapes nearly every debate surrounding prostate cancer screening.

The Promise of Early Detection

To understand why this issue remains controversial, it is important to recognize the strongest argument in favor of screening.

Early detection has been one of the most successful strategies in modern medicine. Finding disease before symptoms develop can create opportunities for intervention that might not exist later. It is therefore understandable why many physicians continue to support screening programs.

The PSA test emerged from this philosophy.

PSA, or prostate-specific antigen, is a protein produced by the prostate gland. Elevated levels can sometimes indicate prostate cancer. Because the test requires only a simple blood draw, it became a widely adopted tool for identifying men who might benefit from further evaluation.

From one perspective, the appeal is obvious. If an abnormal PSA identifies cancer before it spreads, treatment may be more effective and outcomes may improve.

Many physicians continue to view screening through this lens. Their concern is that reducing screening could allow aggressive cancers to go undetected until treatment options become more limited.

This position deserves serious consideration. The goal of screening has always been to reduce suffering and save lives.

The question is whether PSA testing consistently achieves that goal.

Where the PSA Test Becomes Complicated

The challenge with PSA testing is not that it lacks value. The challenge is that PSA is not a cancer test.

It is a prostate test.

PSA levels can rise for many reasons, and cancer is only one of them. Benign prostate enlargement, inflammation, infection, age-related changes, and other non-cancerous conditions can all influence the result.

As a result, an elevated PSA does not necessarily tell us what is wrong. It simply tells us that additional questions may need to be asked.

This uncertainty often creates problems.

Many men hear the words “high PSA” and immediately assume they have cancer. Anxiety begins long before a diagnosis has been established. Additional testing is scheduled. Specialist appointments follow. The possibility of cancer starts to dominate the conversation.

Dr. Petteruti has addressed this issue in episodes such as Managing an Elevated PSA: Avoiding Unnecessary Prostate Biopsies. He emphasized the fact that a single number cannot fully explain what is happening inside the prostate.

The Biopsy Dilemma

When PSA levels raise concern, the next step often involves a prostate biopsy. For many patients, this is the point where uncertainty begins to transform into diagnosis.

A biopsy allows physicians to collect tissue samples and examine them under a microscope. On the surface, the procedure seems straightforward. If cancer is present, the biopsy can identify it.

The problem is that finding abnormal cells is only part of the story.

A biopsy cannot always determine whether those cells will become dangerous in the future. Yet once a patient receives a cancer diagnosis, the psychological impact can be profound. The conversation quickly shifts from monitoring risk to deciding how aggressively to treat the disease.

Biopsies also carry risks of their own. Although serious complications are uncommon, the procedure remains invasive and can lead to bleeding, infection, discomfort, and additional medical interventions.

This is why the biopsy debate extends beyond the procedure itself. The real question is whether every elevated PSA warrants an invasive investigation.

In an Intellectual Medicine podcast, Dr. Petteruti has explored this issue in Think Twice Before a Prostate Biopsy: The Evidence You Need to Hear.

The Problem With Labels

Once abnormal cells are discovered, another challenge emerges: The patient now carries a cancer diagnosis.

For many people, that label changes everything.

The word “cancer” naturally creates urgency. It is difficult to hear that diagnosis without imagining the worst possible outcome. Yet the biology of prostate cancer often refuses to fit neatly into those fears.

After a biopsy, tissue samples are frequently assigned a Gleason score. The score helps describe how abnormal the cells appear under a microscope and provides information about potential aggressiveness.

The problem is that Gleason scores do not predict the future.

They can estimate risk. They can provide probabilities. They cannot determine with certainty how a specific cancer will behave.

Some men with concerning pathology may experience little progression over many years. Others may develop aggressive disease despite appearing relatively low-risk initially.

This uncertainty creates a difficult situation for patients and physicians alike.

Faced with the possibility of progression, many men choose treatment because the alternative feels risky. Yet treatment decisions made under uncertainty can sometimes lead to consequences that are difficult to reverse.

As Dr. Petteruti discussed in Why Gleason Scores Fail Men With Prostate Cancer. In the podcast, he talked about how the score is an important piece of information. The concern is that it is sometimes treated as more predictive than it actually is.

When Treatment Creates New Problems

One of the strongest arguments in the overdiagnosis debate centers on what happens after diagnosis. For men with aggressive disease, these aggressive treatments may provide tremendous benefit.

The challenge arises when the underlying cancer may never have become dangerous in the first place.

Every treatment carries risks. Urinary complications, erectile dysfunction, hormonal side effects, bowel issues, and other quality-of-life concerns can persist long after treatment ends. For some men, these effects become permanent.

This does not mean treatment is wrong, but maybe it means treatment should be proportional to the level of risk.

Dr. Petteruti has discussed the long-term consequences of treatment decisions in one of Intellectual Medicine’s podcast titled Sexual Recovery After Prostate Cancer Treatment: Restoring Function, Confidence, and Quality of Life. These conversations highlight an important reality: treatment outcomes should not be measured solely by whether cancer is removed. Quality of life is just as important.

The Limits of Modern Testing

One reason this debate remains unresolved is that no test can answer the question patients care about most.

What will happen to me?

PSA cannot answer that question.

Biopsies cannot answer that question.

Gleason scores cannot answer that question.

Even advanced genetic testing cannot answer that question with complete accuracy.

Medicine can estimate probabilities, but it cannot predict individual futures.

Two men with similar test results may experience completely different outcomes. One may live for decades without progression. Another may develop aggressive disease despite appearing low-risk at the outset.

This uncertainty frustrates patients, physicians, and researchers alike.

Yet acknowledging uncertainty is not a weakness. It is simply an honest reflection of where the science currently stands.

Looking Beyond the Prostate

The inability to predict outcomes has encouraged many researchers to broaden the conversation. Rather than focusing exclusively on screening tests, some experts have begun paying closer attention to the factors that influence overall health and disease progression.

Some of those factors include:

• Obesity

• Physical inactivity

• Poor diet

• Smoking

• Metabolic disease

• Chronic inflammation

These factors influence far more than cardiovascular health. They may also affect how the body responds to abnormal cells over time.

This broader perspective does not replace screening. Instead, it adds another layer to the discussion.

The Bottom Line

The debate surrounding prostate cancer screening is often framed as a battle between those who support testing and those who oppose it. The reality is far more nuanced.

PSA testing can identify abnormalities. Biopsies can identify cancer. Gleason scores can provide useful information. These tools have value.

What remains uncertain is how that information should be used in every individual case.

An elevated PSA is not a diagnosis. A biopsy finding is not a prediction of the future. A cancer label does not automatically mean treatment is necessary.

The strongest lesson from decades of research may be that finding disease and helping patients are not always the same thing. Sometimes they overlap perfectly. Sometimes they do not.

If You Want To Go Deeper

If this topic matters to you, there are deeper conversations around it that explore how these decisions are made in real clinical settings. Dr. Petteruti discusses this in detail, including how long-term studies shape treatment choices and what they actually reveal about outcomes.

There are also extended notes and resources that break this down further, along with ongoing discussions around lifestyle, recovery, and long-term health decisions.

👉 Join here: https://tinyurl.com/DrPetterutiMember

You can also explore the broader framework behind this approach in Fight Cancer Like a Man, where these ideas are explained in more detail.

👉 https://tinyurl.com/FightLikeAManBook

Thanks for reading! Subscribe for free to receive new posts and support my work.

The test is called MPS2-AS (MyProstateScore 2.0 Active Surveillance). It is a urine test that requires no needle, no tissue sampling, and no disruption of the prostate gland. A urine sample is analyzed for molecular markers that reflect what the prostate produces at the cellular level, reading biological signals rather than physically extracting tissue to search for them. Researchers at Vanderbilt Health evaluated it across 330 men already scheduled for a surveillance biopsy at 11 urology practices across the United States, and the results are worth examining carefully.

This is one of the reasons why Dr. Petteruti, in one of Intellectual Medicine’s viral podcast, Don’t Biopsy Your Prostate Until You Hear This, insisted that biopsy should be the last option or not an option at all for most men.

What the Study Found

The test demonstrated a 99% negative predictive value for high-grade cancer, defined as Grade Group 3 or above. That figure means men who tested negative had approximately a 1 in 100 chance of harboring the kind of cancer that genuinely warrants treatment. Applied to the study cohort, the test would have eliminated roughly 64% of unnecessary biopsies, procedures performed on men who turned out not to have high-grade disease, while missing only about 3% of the higher-grade tumors that do merit clinical attention.

For context, MRI, which has become the dominant noninvasive tool in active surveillance over the past several years, missed around 18% of high-grade upgrades in the same population and avoided only approximately half of unnecessary biopsies. The urine test outperformed imaging on both measures. It also performed consistently in Black patients, a population that faces higher prostate cancer incidence and mortality and is frequently underserved by diagnostic tools validated primarily in other demographic groups.

These are not marginal improvements in diagnostic performance. A 99% negative predictive value is a number that changes clinical decisions, and a 64% reduction in unnecessary biopsies represents a meaningful reduction in procedural burden for a population that has been carrying it for decades without a better alternative.

An Intellectual Medicine podcast has shed light on the fact that there is more to MRI than meets the eye.

Why the Biopsy Treadmill Exists and What It Costs

To understand why this test is significant, it helps to understand the clinical problem it is addressing. A man diagnosed with low-grade prostate cancer and placed on active surveillance has historically faced repeat biopsies every two to three years, not because his cancer is reliably progressing but because the tools available to monitor it have not been precise enough to say with confidence that it is not. That cycle can continue for years. In some cases, it continues for decades.

Each biopsy in that sequence carries real consequences. Pain and bleeding are common. Infection risk, including the small but non-trivial risk of sepsis, accompanies every procedure. There is also the concern around capsule disruption, the physical disruption of the prostate gland’s structural integrity through repeated needle sampling, which has been underweighted in most clinical discussions about the risks of surveillance biopsy.

The deeper problem is that a biopsy samples approximately 1% of the prostate gland through needle cores placed at fixed intervals across the tissue. It cannot reliably confirm what is not present. A negative biopsy does not clear a man. It means nothing was found in the areas sampled during that particular procedure. That fundamental limitation is what drives men back onto the treadmill year after year without resolution, and it is what the molecular approach of MPS2-AS is designed to circumvent.

A Different Philosophy of Monitoring

What MPS2-AS does is read the molecular signals the prostate is actively producing, rather than physically disrupting the gland to search for cells under a microscope. It cannot visualize what cancer looks like histologically. What it can do is detect whether the gland is generating the molecular signatures of high-grade disease, and that is a different and, in many respects, more directly relevant question for a man trying to determine whether his low-grade cancer has changed.

The researchers make a point worth taking seriously. MRI identifies suspicious lesions based on their appearance and location within the gland. It cannot directly assess the molecular behavior of cancer cells. Some tumors that have upgraded to a more aggressive grade do not appear dramatically different on imaging until they have grown considerably. A test that reads molecular output from the prostate may detect those cellular changes earlier than imaging can, before structural changes are visible at all.

This is not simply a better version of an existing tool. It reflects a different underlying logic for how monitoring should work, one that prioritizes the biological activity of the disease over the physical sampling of tissue. That distinction carries implications for how active surveillance is structured, how frequently invasive procedures are scheduled, and how men experience the years of monitoring that follow a low-grade diagnosis.

The Larger Question This Test Does Not Answer

The clinical value of MPS2-AS is real, and a 99% negative predictive value is a meaningful basis for deferring a scheduled biopsy in men who test negative. That is a tool the field has not previously had, and the evidence supporting it is credible enough to warrant serious clinical consideration.

The question the study does not address is the one that sits behind the entire framework of active surveillance. The assumption embedded in surveillance monitoring is that low-grade prostate cancer requires ongoing vigilance for potential upgrading, and that upgrading, when detected, warrants intervention. The ProtecT trial, which followed over 1,500 men for 15 years, found no significant difference in prostate cancer-specific mortality between surgery, radiation, and active monitoring. That finding does not change because a better monitoring test now exists.

What it means is that the procedural burden of active surveillance, the repeated biopsies, the anxiety of recurrent testing, and the accumulated risks of each procedure have been carried by a population of men, a significant proportion of whom were unlikely to die from their cancer regardless of which management path was chosen. A test that reduces that burden is genuinely valuable. It does not, however, resolve the upstream question of how aggressively low-grade prostate cancer should be pursued in the first place.

What This Changes in Practice

Used within a comprehensive monitoring framework, MPS2-AS adds a layer of molecular precision that the field has been missing. Quarterly PSA trend monitoring, PHI scoring, annual non-contrast MRI, and a molecular urine test with a 99% negative predictive value together produce a substantially clearer picture of what is happening inside the prostate gland than any single tool provides in isolation. For a significant proportion of men on active surveillance, that combination could mean years of monitoring pass without a single biopsy being clinically justified.

The biopsy has been treated as the irreducible minimum of prostate cancer monitoring for decades, in part because nothing better was available. This study makes a credible case that it no longer has to occupy that position for most men in active surveillance. Whether that case is adopted into routine clinical practice will depend on how quickly the evidence diffuses into a field that has historically been slow to reduce procedural reliance even when the data supports doing so.

For men currently on active surveillance, the existence of this test is a reason to ask their urologist a direct question: given a 99% negative predictive value for high-grade disease, what is the clinical justification for scheduling a biopsy before this test has been used? That question has a reasonable answer in some cases. In many others, it may not.

The Intellectual Medicine podcast has covered the evidence on active surveillance, biopsy risk, and noninvasive monitoring in detail. For any man navigating a low-grade prostate cancer diagnosis, those conversations provide the clinical context that most surveillance appointments do not.

If You Want To Go Deeper

If this topic matters to you, there are deeper conversations around it that explore how these decisions are made in real clinical settings. Dr. Petteruti discusses this in detail, including how long-term studies shape treatment choices and what they actually reveal about outcomes.

There are also extended notes and resources that break this down further, along with ongoing discussions around lifestyle, recovery, and long-term health decisions.

👉 Join here: https://tinyurl.com/DrPetterutiMember

You can also explore the broader framework behind this approach in Fight Cancer Like a Man, where these ideas are explained in more detail.

👉 https://tinyurl.com/FightLikeAManBook

Thanks for reading! Subscribe for free to receive new posts and support my work.

Most people think about obesity in terms of appearance, clothing sizes, or physical limitations. Those concerns are understandable. But they can also distract from a much bigger issue. Excess body fat does not simply sit beneath the skin. It changes how the body functions. It alters hormones, increases inflammation, places strain on vital organs, and affects systems that most people rarely think about until something goes wrong.

The consequences often unfold quietly.

A person may feel relatively healthy today while harmful changes are developing inside the body. Years later, those changes can appear as heart disease, diabetes, cancer, kidney failure, or severe joint problems. By then, the damage may already be well underway.

This is what makes obesity different from many other health conditions. The most serious risks are often the ones people do not feel until much later.

In the Intellectual Medicin podcast episode The Real Obesity Problem: Aging Faster, Losing Muscle, and Getting It Wrong, Dr. Stephen Petteruti discussed a point that often gets overlooked. The conversation around obesity frequently focuses on body weight while ignoring the broader biological changes happening beneath the surface. Those hidden changes may ultimately be the greatest threat.

So what exactly makes obesity so dangerous?

Obesity Is More Than Excess Weight

Most people know obesity as a condition involving excess body fat. Clinically, it is often defined using body mass index, or BMI. A BMI of 30 or higher is generally classified as obesity.

But obesity is much more than a mathematical calculation.

Fat tissue is not simply stored energy. It is biologically active. It releases hormones, inflammatory chemicals, and signaling molecules that influence nearly every system in the body.

This distinction matters because many people still think of obesity primarily as a cosmetic issue. Medicine sees it differently.

Healthcare professionals increasingly recognize obesity as a chronic disease that affects metabolism, hormone function, cardiovascular health, kidney function, joint health, and even cancer risk. The effects extend far beyond body weight itself.

This is one reason obesity can be so difficult to address. The condition is rarely caused by a single factor.

Diet plays a role. Physical activity plays a role. Genetics, sleep quality, medications, stress, hormones, and environmental factors can also contribute. In many cases, obesity develops from a combination of influences acting over many years.

The Question Most People Should Be Asking

When discussions about obesity arise, the conversation is often centered around how a person looks. That brings us to questions that millions of people are finding an answer to:

• How much weight should I lose?

• What diet works best?

• How quickly can I see results?

Those questions are understandable, but they may miss the bigger picture. A more important question might be:

• What happens if obesity remains untreated for the next ten or twenty years?

The answer to that question is the exact reason why physicians take the condition seriously.

The risks extend into nearly every major organ system. Some develop gradually. Others appear after years of accumulated damage. Many share a common thread: chronic inflammation, metabolic dysfunction, and hormonal disruption.

Let’s examine five of the most important long-term risks.

1. Cancer: A Risk Many People Never Connect to Obesity

When people think about cancer risk, obesity is rarely the first factor that comes to mind. Smoking, genetics, environmental exposures, and family history tend to receive most of the attention.

Yet obesity has emerged as one of the most important preventable risk factors for several forms of cancer. The relationship is not entirely surprising when you consider what excess body fat does inside the body.

Fat tissue can alter hormone levels. It can increase inflammation. It can affect insulin signaling and create biological conditions that encourage abnormal cell growth. Over time, those changes may increase the likelihood of cancer development.

Research has linked obesity to higher risks of several cancers, including cancers of the colon, rectum, breast, uterus, gallbladder, and prostate. The connection becomes especially concerning because cancer often develops silently.

There are usually no warning signs during the earliest stages. By the time symptoms appear, treatment can become more complicated. This is why cancer prevention discussions increasingly include weight management.

In his episode Why You’re Aging Faster Than You Should, Dr. Petteruti explored how chronic inflammation contributes to many age-related diseases. Cancer represents one example of how prolonged inflammation may influence long-term health outcomes.

While obesity does not guarantee cancer will develop, the evidence suggests it can create an environment that makes cancer more likely.

2. Cardiovascular Disease: The Heart Pays a Price

The cardiovascular system is often one of the first major systems affected by obesity.

The reason is simple.

Extra body mass requires extra work.

The heart must pump blood through a larger body. Over time, that additional workload places significant strain on the cardiovascular system.

At first, the body adapts.

Eventually, problems begin to emerge. Blood pressure rises. Cholesterol levels become less favorable. Fatty deposits accumulate inside arteries. Blood flow becomes restricted. The process may take years, but the consequences can be devastating.

Heart attacks, strokes, heart failure, and other cardiovascular conditions remain among the leading causes of death worldwide.

Obesity does not operate in isolation. It often appears alongside high blood pressure, insulin resistance, and metabolic dysfunction. Together, these factors create a combination that can significantly increase cardiovascular risk.

One of the challenges is that many people feel perfectly fine while these changes are occurring. High blood pressure often produces no symptoms. Arterial plaque develops silently. And the first warning sign may be a medical emergency.

This is one reason prevention receives so much attention in modern medicine.

As Dr. Petteruti discussed in Why Modern Healthcare Is Failing Prevention | How to Actually Improve Your Health, many chronic diseases become far more difficult to manage once symptoms finally appear. The greatest opportunities often exist years before diagnosis.

3. Type 2 Diabetes: The Disease That Changes Everything

Few conditions illustrate the connection between obesity and chronic disease more clearly than type 2 diabetes. The link is so strong that many experts view obesity as one of the primary drivers of the modern diabetes epidemic.

The process often begins with insulin resistance.

Under normal circumstances, insulin helps move glucose from the bloodstream into cells where it can be used for energy. As body fat increases, cells may become less responsive to insulin. The pancreas compensates by producing more. For a while, that strategy will work.

Eventually, however, the pancreas may struggle to keep pace with demand. Blood sugar levels begin rising and Type 2 diabetes develops.

The condition affects far more than blood glucose.

Over time, elevated blood sugar can damage blood vessels, nerves, kidneys, eyes, and the cardiovascular system. Many people think of diabetes as a single disease. In reality, it often becomes the starting point for numerous complications.

The encouraging news is that modest changes can produce meaningful benefits. Research consistently shows that losing even 5% to 7% of body weight can improve insulin sensitivity and reduce diabetes risk in many individuals.

That finding highlights an important principle. Health improvements do not always require dramatic transformations. Sometimes relatively small changes can have significant biological effects.

4. Osteoarthritis: The Risk That Limits Mobility

Most discussions about obesity focus on internal organs. The musculoskeletal system deserves attention as well. Every step places force through the knees, hips, ankles, and spine. As body weight increases, those forces increase too.

Over years, the additional stress can accelerate wear and tear within joints. Cartilage gradually deteriorates.

Pain develops.

Movement becomes more difficult.

Simple activities such as climbing stairs, walking long distances, or standing for extended periods may become increasingly challenging. But the story extends beyond mechanics.

Researchers now understand that fat tissue produces inflammatory substances that may contribute to joint damage independently of weight-bearing forces. In other words, obesity may affect joint health through both physical and biological pathways.

This distinction is important because osteoarthritis is not merely an inconvenience. Loss of mobility often creates a cascade of additional problems.

• Physical activity decreases.

• Muscle mass declines.

• Weight gain becomes easier.

Overall health can deteriorate further.

In his episode Building Strong Bones: Unlock the Secret to Longevity and Vitality, Dr. Petteruti emphasized the importance of maintaining musculoskeletal health as we age. Strong bones and healthy joints play a critical role in preserving independence and quality of life.

5. Chronic Kidney Disease: The Hidden Threat

Among all the long-term risks associated with obesity, chronic kidney disease may be one of the least appreciated. Most people do not associate excess weight with kidney function. The connection, however, is stronger than many realize.

The kidneys act as the body’s filtration system. They remove waste products, regulate fluid balance, and help maintain numerous physiological processes. Obesity places those organs under considerable strain. Part of the problem occurs indirectly. Obesity increases the likelihood of developing high blood pressure and type 2 diabetes, which remain the leading causes of kidney failure.

Part of the problem occurs directly. Excess body weight forces the kidneys to filter larger volumes of blood. Initially, the kidneys compensate by working harder.

Over time, that increased workload may damage delicate filtering structures within the organs. The progression is often slow. Symptoms may not appear until substantial kidney function has already been lost. This is one reason chronic kidney disease can be so dangerous.

Many individuals are unaware there is a problem until the disease has reached an advanced stage. In severe cases, kidney failure may eventually require dialysis or transplantation.

The Bigger Picture

One of the biggest mistakes people make is viewing obesity as a single problem with a single consequence. The reality is far more complicated.

• Obesity affects hormones.

• It affects inflammation.

• It affects metabolism.

• It affects blood vessels, organs, joints, and cellular function.

That is why the condition appears repeatedly across so many major diseases such as cancer, heart disease, diabetes, osteoarthritis, kidney disease.

These conditions may look different on the surface, but many share common underlying pathways influenced by excess body fat.

This perspective changes the conversation.

The Bottom Line

Obesity is often discussed as a weight problem. The evidence suggests it is much more than that.

Excess body fat can influence nearly every system in the body, increasing the risk of cancer, cardiovascular disease, type 2 diabetes, osteoarthritis, chronic kidney disease, and numerous other health conditions.

The encouraging news is that meaningful benefits can occur before dramatic weight loss happens. Even modest improvements in body weight, physical activity, sleep quality, and nutrition can produce measurable health gains.

The most important lesson is that obesity should not be evaluated solely by what appears in the mirror. Its greatest impact often occurs where people cannot see it.

And those hidden effects are often the ones that shape long-term health the most.

Click here to subscribe for more Substack posts like this one.

If You Want To Go Deeper

If this topic matters to you, there are deeper conversations around it that explore how these decisions are made in real clinical settings. Dr. Petteruti discusses this in detail, including how long-term studies shape treatment choices and what they actually reveal about outcomes.

There are also extended notes and resources that break this down further, along with ongoing discussions around lifestyle, recovery, and long-term health decisions.

👉 Join here: https://tinyurl.com/DrPetterutiMember

You can also explore the broader framework behind this approach in Fight Cancer Like a Man, where these ideas are explained in more detail.

👉 https://tinyurl.com/FightLikeAManBook

Thanks for reading! Subscribe for free to receive new posts and support my work.

For decades, men have been told a simple story: testosterone fuels prostate growth, prostate growth causes urinary symptoms, and lowering testosterone helps solve the problem. It sounds logical. Unfortunately, human biology is rarely that straightforward.

Many men begin struggling with urinary symptoms during the very stage of life when testosterone levels are declining. Others avoid discussing fatigue, low libido, loss of muscle mass, and other symptoms of low testosterone because they worry treatment could make their prostate problems worse.

The result is confusion. And when confusion meets fear, bad decisions often follow.

Men start supplements without understanding what they do. They begin medications without fully appreciating the tradeoffs. Some even assume that frequent urination automatically means cancer.

The reality is far less dramatic.

An enlarged prostate is one of the most common changes that occurs with aging. It can be frustrating. It can disrupt sleep. It can affect quality of life. But it is not the same thing as prostate cancer, and understanding that distinction is the first step toward making better decisions.

What Are We Really Talking About?

Before discussing treatments, supplements, or hormones, it helps to define the problem.

Benign prostatic hyperplasia (BPH) is a non-cancerous enlargement of the prostate gland. As the prostate grows, it can place pressure on the urethra, making it more difficult for urine to pass normally.

The symptoms are familiar to many men:

• Frequent urination

• Waking up at night to urinate

• A weak urinary stream

• Difficulty starting urination

• Feeling that the bladder never fully empties

These symptoms often develop gradually. In many cases, men do not notice how much things have changed until nighttime bathroom trips become routine. One of the challenges is that urinary symptoms often trigger fear long before they trigger understanding.

Dr. Petteruti has addressed this issue in several discussions about prostate health, including episodes focused on PSA testing, elevated PSA levels, and prostate cancer screening. A recurring theme is that symptoms and diagnoses are not the same thing. A symptom tells us something deserves attention. It does not really tell us what the problem is.

That distinction becomes important when men start looking for answers.

The Question Most Men Never Ask

When urinary symptoms appear, most men immediately ask:

“What can I take to fix this?”

A better question might be:

“Why is this happening in the first place?”

That question receives surprisingly little attention.

Many discussions about BPH focus almost entirely on symptom management. There is nothing wrong with symptom relief. Sleep matters. Comfort matters. Quality of life matters. But knowing what drives prostate enlargement may provide a much more useful framework for long-term health.

This brings us to one of the most persistent beliefs in men’s health.

Does Testosterone Cause Prostate Enlargement?

For many years, conventional wisdom suggested that testosterone was a major driver of prostate growth.

And if we are to rely on logic, the idea seems reasonable.

The prostate is influenced by male hormones. Testosterone is the primary male hormone. Therefore, more testosterone should mean more prostate growth.

The problem is that the relationship does not appear to work that way in the real world.

Young men typically have the highest testosterone levels of their lives. Yet they rarely experience the urinary symptoms commonly associated with BPH. Those symptoms become increasingly common later in life, often as testosterone levels are declining.

This observation alone should raise questions.

Dr. Petteruti has examined this issue extensively in episodes such as The Truth About Testosterone: Does It Really Cause Prostate Cancer?

The common thread throughout those discussions is that testosterone is often blamed for prostate problems without sufficient evidence to support the claim.

That does not mean hormones are irrelevant.

It means the story is more complicated.

One hormone that frequently enters the conversation is dihydrotestosterone, or DHT. DHT is derived from testosterone and plays an important role within prostate tissue. However, acknowledging that DHT is involved does not prove that increasing testosterone automatically causes unlimited prostate growth.

The biology is far more nuanced than that.

What Actually Drives Prostate Growth?

If testosterone is not the primary explanation, what is?

The honest answer is that researchers still do not fully understand every factor involved. However, several themes appear repeatedly throughout the scientific literature.

Inflammation is one of them.

As men age, many develop low-grade chronic inflammation throughout the body. Excess body fat, poor sleep, physical inactivity, chronic stress, and metabolic dysfunction can all contribute to this process.

Inflammation does not just affect the heart or blood vessels. It influences tissues throughout the body, including the prostate.

Another factor is oxidative stress.

This refers to cellular damage caused by an imbalance between free radicals and the body’s antioxidant defenses. Over time, oxidative stress may contribute to many age-related changes, including those seen within prostate tissue.

Body composition also deserves attention.

Men carrying excess abdominal fat often experience hormonal and inflammatory changes that affect multiple organ systems simultaneously.

This is one reason why prostate health cannot always be separated from overall health.

In his episode The Real Obesity Problem: Aging Faster, Losing Muscle, and Getting It Wrong, Dr. Petteruti discussed how excess body fat influences far more than appearance. The effects extend into hormones, inflammation, metabolism, and long-term health outcomes.

The prostate may simply be another piece of that larger picture.

Why Patience Matters More Than Most Men Realize

One of the biggest mistakes men make when dealing with BPH is expecting quick results.

That expectation sets many people up for disappointment. The prostate usually does not enlarge overnight. In most cases, the process unfolds gradually over years or even decades.

Improvement often follows a similar timeline. A man may begin exercising, improve his diet, lose weight, start a supplement, or begin medication. After a few weeks, he notices little change and concludes that nothing is working.

But prostate health rarely operates on a short timeline.

Supplements: Hope, Hype, and Reality

Few areas of men’s health generate as much confusion as supplements. Walk into any pharmacy, and you will find shelves filled with products promising better urinary flow, prostate support, and relief from nighttime urination.

The challenge is separating marketing from evidence.

Saw palmetto remains one of the most popular prostate supplements available today. Its reputation has grown to the point where many men assume it is the natural solution for BPH.

The evidence, however, is mixed.

Some men report improvements. Others notice little difference even after months of use. Don’t get it mixed up because this does not necessarily mean saw palmetto is useless. It means the benefits may be smaller and less predictable than advertising often suggests.

In one of Intellectual Medicine’s podcasts, Dr. Petteruti extensively looked at similar challenges in his episode, The Truth About Prostate Supplements: My A-C Grades on What Really Works

Watch the full episode here:

A recurring lesson from those discussions is that ingredients alone do not determine outcomes.

Dosage must be consistent.

How the supplements are formulated means a lot.

And, importantly, the patient must have realistic expectations.

Although this is a luxury, patience must be in the picture.

When Medications Enter the Conversation

For men with more disruptive symptoms, prescription medications often become part of the discussion.

Two commonly prescribed options are finasteride and dutasteride.

Unlike many supplements, these medications target a specific biological pathway. They reduce DHT activity within the prostate and can gradually shrink the gland over time.

Many men experience improvements in urinary flow and fewer nighttime bathroom visits. However, the benefits usually take months to appear. There are also tradeoffs.

Some men report changes in libido, erectile function, or sexual performance. Others tolerate the medications without significant problems.

This is why treatment decisions should rarely be reduced to simple slogans. Every intervention involves potential benefits and potential drawbacks. The right choice depends on symptoms, priorities, risk tolerance, and overall health.

The Bigger Picture

One of the most interesting aspects of BPH is that it often reflects larger processes occurring throughout the body. When discussions focus only on the prostate, it is easy to miss this point.

The same factors associated with metabolic dysfunction, excess body fat, poor sleep, physical inactivity, and chronic inflammation may also contribute to worsening urinary symptoms. This helps explain why some men experience improvements when they address broader health issues rather than focusing exclusively on the prostate itself.

Exercise, weight management, sleep quality, and stress reduction may not sound as exciting as a new supplement or medication. But they influence many of the underlying processes believed to contribute to prostate enlargement.

That does not mean lifestyle changes eliminate the need for medication or other treatments. It means the foundation often extends beyond the prostate itself.

The Bottom Line

The story most men hear about BPH is often too simple.

An enlarged prostate is not the same thing as prostate cancer. Testosterone does not appear to be the primary driver of prostate enlargement. And meaningful improvements rarely happen overnight.

The evidence points toward a more complex picture involving aging, inflammation, body composition, metabolic health, and changes within the prostate itself. Supplements may help some men. Medications may help others. Surgery may be appropriate in certain situations.

But before choosing any treatment, it is worth understanding the question that matters most: Are you treating a symptom, or are you addressing the factors that may be contributing to it?

The answer may shape not only your prostate health, but your overall health as well.

If You Want To Go Deeper

If this topic matters to you, there are deeper conversations around it that explore how these decisions are made in real clinical settings. Dr. Petteruti discusses this in detail, including how long-term studies shape treatment choices and what they actually reveal about outcomes.

There are also extended notes and resources that break this down further, along with ongoing discussions around lifestyle, recovery, and long-term health decisions.

👉 Join here: https://tinyurl.com/DrPetterutiMember

You can also explore the broader framework behind this approach in Fight Cancer Like a Man, where these ideas are explained in more detail.

👉 https://tinyurl.com/FightLikeAManBook

Thanks for reading! Subscribe for free to receive new posts and support my work.

This is true even when published research supports it. That is not a claim about bad doctors. It is a fact about how the medical system works. A whole category of treatment has real biological promise and decades of safety data behind it, yet it sits almost entirely outside the conversation most men have after a diagnosis. That category is repurposed drugs, and the silence around it deserves a closer look.

A repurposed drug is a medication built for one disease that researchers later find may help with a different one. The idea is not new or fringe. Doctors have prescribed medications off-label for decades. The controversy starts only when the disease in question is cancer. The stakes feel higher, the fear runs deeper, and the system grows far more cautious.

Why So Few Patients Hear About These Options

The real question is not whether repurposed drugs should replace conventional cancer treatment. For most men, that framing is wrong from the start. The better question is why so few patients are ever told these options exist. The answer lies in how medicine is structured, not in the strength of the evidence.

Oncologists and surgeons are expected to work within established standards of care. Those guidelines exist for good reasons, including patient safety and professional accountability. The problem is that repurposed drug protocols often fall outside those guidelines. When a doctor avoids the topic, it usually does not mean the treatment fails. It means the doctor is staying inside the boundary of what they can safely recommend.

There is also a simple limit on time and attention. No physician can master every new area of medicine. Most focus on treatments already built into mainstream practice. As a result, a patient who wants to explore repurposed drugs often ends up researching alone. The information is real. It just has no place in a standard oncology visit. This is a topic Dr. Petteruti has talked about in an one of the Intellectual Medicine viral Podcast

Click here to watch the full podcast

The Bias Problem in How Evidence Reaches You

Before looking at any specific drug, it helps to know that the information reaching patients rarely tells the full story. Most people assume a published study reflects objective reality. The truth is more complicated because there are biases that shapes what patients end up believing.

The first is publication bias. Positive results get published more often than negative ones. When a treatment performs poorly, there is little enthusiasm to share those findings. Over time, this makes successful outcomes look more common than they really are.

The second is interpretive bias. A study might report that a treatment improves survival, and that can be technically true. What patients rarely hear is how small that benefit actually is. Adding a few months of survival can reach statistical significance. Yet many patients would weigh that gain very differently once they understood the side effects and the cost. Spotting these biases does not mean rejecting medicine. It means asking sharper questions about real-world benefit.

Dr. Petteruti has spent considerable time on exactly how this plays out in prostate cancer, where the gap between a statistically significant result and a meaningful one drives many treatment decisions. He breaks down how that gap gets used to sell intervention in his episode, How Fear Sells Prostate Cancer Treatment, which is worth watching before you accept any survival claim at face value.

Here’s the full episode:

How to Tell a Legitimate Repurposed Drug From a Hopeful Claim

Not every promising claim deserves equal trust. Cancer patients face a constant flood of testimonials and alternative recommendations, and many have little evidence behind them. A few simple principles help separate serious candidates from wishful thinking.

Safety comes first. Prostate cancer is often a long-term disease, so a treatment may need to be used for years. A drug that can cause real harm is hard to justify when the benefit stays uncertain. This is exactly why drugs with long safety records become the most interesting candidates.

The quality of evidence comes next, and it works as a ladder. Laboratory studies offer early clues, but results in a petri dish do not always help real patients. Animal studies move one step closer. Case reports and patient experiences add more detail. No single level should stand alone. Real confidence comes when several independent forms of evidence point the same way. A treatment supported only by testimonials has not cleared the bar a serious disease demands.

The Red Flags Worth Watching For

As interest in repurposed drugs grows, the harder task is spotting oversimplified promises. Many protocols are sold with a confidence that makes them sound more certain than they are. For a frightened patient, that confidence can be dangerously convincing.

The clearest red flag is any program claiming that one drug fixes everything. Cancer is not a single disease with a single pathway. Even within prostate cancer, tumors behave differently and progress at different rates. A one-size-fits-all plan rarely reflects the real complexity of the disease. A second warning sign is the absence of personalization. A solid plan accounts for your age, health, disease stage, and other conditions.

Be cautious about any protocol that pushes self-treatment without professional guidance. Repurposed drugs may be familiar, but familiar does not mean risk-free. Dosing, timing, drug interactions, and monitoring still require real oversight. The strongest protocols stay flexible and open to adjustment as your situation changes.

The Specific Drugs Under Investigation

Two repurposed compounds come up again and again in prostate cancer discussions. Each one shows both the promise and the limits of the current evidence.

Sirolimus draws attention because of its effect on a pathway called mTOR. This pathway controls cell growth, division, and metabolism. The logic is simple. Cancer cells rely on growth signals to multiply. Too much mTOR activity seems to feed that process. By partly blocking the pathway, sirolimus may slow the growth of certain cancer cells. Lab studies, animal research, and early clinical work all suggest possible benefit. The evidence is growing, but it remains incomplete. For now, sirolimus is a real area of scientific interest rather than a proven treatment.

Low-dose naltrexone, often called LDN, generates similar discussion. Research suggests it may affect immune function, inflammation, and cellular activity. Those effects could influence how cancer cells survive. Its appeal is helped by a well-understood safety profile and a low cost. Doctors already have years of experience using it for other conditions. Still, the large clinical trials are limited. LDN is best understood as ongoing research, not a settled answer.

Sirolimus and LDN are only two entries in a much longer list, and understanding how they fit into a complete protocol takes more than a summary of each drug. Dr. Petteruti has built much of his clinical work around these repurposed compounds, and he lays out the full reasoning, including how he combines them and why, in his episode, Fight Prostate Cancer Like a Man: Avoid Regret, Reclaim Your Power Using Repurposed Drug Therapy. It is the clearest place to hear how an experienced physician actually applies this approach in practice.

Watch the full episode here:

Why Prostate Cancer Invites This Conversation

Prostate cancer does not always behave like other cancers. That difference sits at the center of why repurposed drugs deserve serious discussion here. Many cancers grow fast and demand immediate action. A large share of prostate cancers stay inside the gland for years. Some grow so slowly they never threaten a man’s life at all.

This is why active surveillance has become an accepted option for many patients. It is also why quality of life often carries as much weight as quickly shrinking a tumor. That slower course creates a genuine window. There is often time to think, compare options, and consider approaches designed for long-term management. Whether repurposed drugs prove valuable in that window is still debated. The window itself, though, is real, and it changes how quickly a man truly needs to act.

Active surveillance is not as simple as it sounds, though, and it fails some men while serving others well. Dr. Petteruti examines exactly where that line falls, and who should be cautious about it, in his episode, Active Surveillance for Prostate Cancer: When “Watchful Waiting” Fails Men. It is essential listening for anyone weighing whether that window applies to their own situation.

Where Dr. Petteruti Stands

Dr. Petteruti takes a sharper position than the careful neutrality that surrounds most of this topic. His view is worth stating plainly. He argues that treatment should be judged against your overall health, not the cancer alone. That single shift changes everything.

Many men diagnosed with prostate cancer are far likelier to die from heart disease than from the cancer. A treatment that controls a tumor while damaging the heart may not serve the patient at all. The same is true of treatments that strip away testosterone, muscle, and energy. Tumor control on paper is not the same as a life worth living.

This is where repurposed drugs connect to something larger. Some compounds may act on several pathways at once. They might support heart and metabolic health while also showing anti-cancer potential. The appeal is that they treat the man, not only the tumor. The idea of synergy follows the same logic. Cancer uses many survival mechanisms, so combining therapies that hit different targets may work better than any single drug alone.

The decision, in the end, belongs to the patient. Doctors recommend, researchers present data, and families share opinions. None of them live with the result. Decisions made from knowledge consistently beat decisions made from fear, and widening this conversation is how men gain that knowledge.

If You Want To Go Deeper

If this topic matters to you, there are deeper conversations around it that explore how these decisions are made in real clinical settings. Dr. Petteruti discusses this in detail, including how long-term studies shape treatment choices and what they actually reveal about outcomes.

There are also extended notes and resources that break this down further, along with ongoing discussions around lifestyle, recovery, and long-term health decisions.

👉 Join here: https://tinyurl.com/DrPetterutiMember

You can also explore the broader framework behind this approach in Fight Cancer Like a Man, where these ideas are explained in more detail.

👉 https://tinyurl.com/FightLikeAManBook

Thanks for reading! Subscribe for free to receive new posts and support my work.

That finding comes from a recent study published in the International Journal of Cancer and adds to the ongoing discussion about the benefits and limitations of PSA screening in older men. It also reflects a concern that has been raised for years: finding prostate cancer is not always the same as finding a dangerous disease.

The researchers analyzed long-term data from the UK CAP trial, which followed more than 400,000 men, and combined those findings with mortality data from England. Their goal was to estimate how often PSA screening leads to overdiagnosis. Overdiagnosis occurs when a cancer is detected that would never have become clinically significant during a man’s lifetime. In other words, the cancer is real, but it would not have caused symptoms, required treatment, or affected how long the person lived.

The results were difficult to ignore. As men age, the likelihood of overdiagnosis increases substantially because the chance of dying from other causes rises while many prostate cancers remain slow-growing. This means a growing number of older men may be diagnosed with cancers that are unlikely to threaten their health but may still expose them to additional testing, biopsies, treatment decisions, and the anxiety that often follows a cancer diagnosis.

Click here to see what doctor Peterutti have to say on PSA

What the Numbers Actually Show

The study found that the likelihood of overdiagnosis rises sharply with age. For a man diagnosed with prostate cancer through PSA screening at age 50, researchers estimated that about 16% of those cancers would never have been detected within the next 15 years if screening had not occurred. By age 70, that figure increased to 32%. By age 80, it reached 58%.

The trend is difficult to ignore. As men get older, the chances increase that a cancer found through PSA screening was never going to become a serious health problem. In many cases, the cancer exists, but it grows so slowly that it would never have caused symptoms or affected the man’s lifespan.

For men in their later years, this changes how screening results should be interpreted. A positive PSA test does not automatically mean a dangerous cancer has been found. In fact, the study suggests that for many older men, especially those around age 80, a screen-detected cancer is more likely to represent a condition that would have remained unnoticed for the rest of their lives.

This is why age plays such an important role in screening decisions. The older a man becomes, the greater the chance that screening will identify a cancer that is real but unlikely to ever cause harm.

Why This Happens

The reason behind these findings becomes clearer when the biology of prostate cancer is understood. PSA screening can detect cancers that are present in the prostate, but many prostate cancers grow very slowly. Some remain inactive for years or even decades without causing symptoms or threatening a man’s health.

As men age, the likelihood of dying from other causes increases substantially. Conditions such as heart disease, stroke, and other illnesses become much more common. This means that many older men are more likely to die from something unrelated to their prostate cancer before the cancer ever becomes a clinical problem.

The researchers measured this directly. They found that the risk of dying from causes other than prostate cancer within 15 years of a PSA test was about 10% at age 50. By age 70, that figure increased to 49%, and by age 80 it reached 89%. As the risk of dying from other causes rises, the chance that a screen-detected prostate cancer will ever become life-threatening falls dramatically.

This is why overdiagnosis is more than a statistical concept. A diagnosis often leads to further testing, specialist visits, biopsies, and discussions about treatment. In some cases, it can lead to surgery, radiation, or hormone therapy, each of which carries its own risks and side effects. When the cancer was never going to cause harm in the first place, the burden created by the diagnosis and treatment may end up being greater than the burden of the disease itself.

Click here to learn more about “The Hidden Cost of Androgen Deprivation Therapy in Prostate Cancer.”

What the Lead Researcher Said

The lead author, Dr. Adam Brentnall of Queen Mary’s Wolfson Institute, was unusually direct in his conclusions. He stated that the current policy of PSA testing on demand has produced high rates of opportunistic testing in older men who face a high risk of harm from overdiagnosis. Screening men over 70, in his assessment, is unlikely to reduce mortality. The harms in that age group are real and documented. The benefit, in the data, is not present.

That is a notable statement coming from within the research establishment, because it aligns with a position that has frequently been treated as contrarian when stated outside it. The system is beginning to articulate what the evidence has supported for some time.

How This Fits the Broader Evidence

This study does not exist in isolation, and its significance grows when it is placed alongside two other well-established bodies of evidence.

The autopsy literature has shown for decades that prostate cancer is present in 30 to 60 percent of men over 60 who die from unrelated causes. These men never knew the cancer was there. They were never harmed by it. Their immune system, the structural containment of the prostate capsule, and their underlying biology kept the disease contained for their entire lives. The cancer existed and remained clinically irrelevant from diagnosis-that-never-happened to death-from-something-else.

The ProtecT trial followed over 1,500 men for 15 years across three management approaches, surgery, radiation, and active monitoring, and found no statistically significant difference in prostate cancer-specific mortality between the three groups. Approximately 97% of men across all three groups were still alive at 15 years. The aggressive interventions did not produce a survival advantage over careful monitoring.

Click here to learn more:

Combine those two bodies of evidence with the new UK finding that overdiagnosis risk reaches 58% in men screened at 80, and the picture becomes difficult to argue with. A significant proportion of men diagnosed with prostate cancer today, particularly older men, are being diagnosed with a condition that would never have shortened their lives. They are then subjected to treatments that reliably reduce quality of life in exchange for a survival benefit that the data does not show exists.

What the Researchers Got Right About Health and Age

The authors made an important distinction that deserves attention because it reflects the biology directly rather than serving as a footnote to the findings. They noted that health is more than a number based on age and that the risk of overdiagnosis may be lower in men who are in generally good health and follow healthy lifestyle habits.

That observation carries real weight. A man in his 60s with excellent metabolic health, low body fat, strong immune surveillance, controlled inflammation, and a low toxic burden occupies a very different biological position from a man of the same age with metabolic syndrome, elevated inflammatory markers, and poor body composition. The slow-growing prostate cancer that remains harmless in one internal environment may behave differently in another. Lifestyle is not a side issue in this conversation. It sits at the center of it because the same diagnosis can carry very different implications depending on the biology of the man receiving it. For readers interested in understanding this connection more deeply,

Dr. Petteruti explores the role of metabolic health in long-term disease outcomes in his podcast episode titled “Why Modern Healthcare Is Failing Prevention.”

Click here to watch the podcast

The researchers also acknowledged that their data predates the widespread use of MRI-targeted biopsy, which is expected to reduce overdiagnosis by identifying slower-growing cancers before a needle ever enters the gland. That is a meaningful development worth recognizing. MRI, when combined with PSA density and PHI scoring, provides a far more reliable picture of what is happening inside the prostate than PSA testing alone.

The Principle That Does Not Change

The fundamental point this study validates remains constant regardless of advances in imaging. PSA is a signal, not a verdict. A rising number in an older man is not an automatic trigger for intervention. The trend over time, the full clinical picture, the man’s age and overall health, and the honest probability that a detected cancer will ever cause him harm all belong in the conversation before any decision is made.

For many men, and particularly for older men, the greatest risk associated with prostate cancer screening is not the cancer itself. It is what happens after the cancer is found. The diagnosis sets in motion a sequence of decisions that can permanently alter a man’s life, and a substantial fraction of those decisions are made in response to a cancer that was never going to threaten the man who carries it.

The system is finally beginning to say what has been the position here from the beginning. That is worth paying attention to, and it is worth bringing into the room the next time a physician recommends a PSA test as though the answer were obvious.

If You Want To Go Deeper

If this topic matters to you, there are deeper conversations around it that explore how these decisions are made in real clinical settings. Dr. Petteruti discusses this in detail, including how long-term studies shape treatment choices and what they actually reveal about outcomes.

There are also extended notes and resources that break this down further, along with ongoing discussions around lifestyle, recovery, and long-term health decisions.

👉 Join here: https://tinyurl.com/DrPetterutiMember

You can also explore the broader framework behind this approach in Fight Cancer Like a Man, where these ideas are explained in more detail.

👉 https://tinyurl.com/FightLikeAManBook

Thanks for reading! Subscribe for free to receive new posts and support my work.

A clean scan at a given point in time confirms that no visible tumor was detected during that imaging session. It does not confirm that every cancer cell has been eliminated, that recurrence is no longer biologically possible, or that the conditions that allowed the cancer to develop in the first place have been resolved. For a significant proportion of cancer survivors, the reassurance embedded in the phrase “cancer-free” produces a level of confidence that the underlying evidence does not support.

Dr. Petteruti has explored this question in detail, examining both the clinical data on delayed relapse and the broader problem of how survival statistics are communicated to patients. The full conversation is worth your time.

What a Clean Scan Actually Tells You

Imaging technology detects tumors at a resolution determined by lesion size and density, relative to the sensitivity of the equipment used. A CT scan, PET scan, or MRI that returns no visible evidence of disease means nothing was found above the detection threshold at that moment. It does not mean nothing is there.

Cancer cells operating below the imaging threshold are not captured by the scan and do not appear in the report. The clinical notation of “no evidence of disease” reflects the limits of the technology as much as it reflects the patient’s biology.

This is not a theoretical concern. Breast cancer provides one of the most well-documented examples of delayed relapse in oncology. Some women who had no detectable disease for years, in some cases more than a decade, later presented with recurrence in the bones, liver, or other distant sites. The cancer did not develop gradually in those years. It remained biologically present in a dormant state before reactivating. The scan that declared them cancer-free was accurate within the limits of what it could detect. It was not accurate as a statement about the complete absence of disease.

The clinical habit of anchoring reassurance to the five-year mark, rather than to a more honest account of what the evidence shows about long-term recurrence risk in specific cancer types, does patients a disservice that only becomes apparent when the recurrence arrives.

Subscribe now

When Scanning More Does Not Save More Lives

The intuitive logic of cancer surveillance is that earlier detection of recurrence leads to earlier treatment, which in turn leads to better outcomes. That sequence is coherent and, in some clinical scenarios, holds. The problem is that several studies examining surveillance intensity after cancer treatment have failed to demonstrate a meaningful survival advantage for patients who receive more frequent imaging compared to those monitored less aggressively.

This finding challenges a deeply held assumption in both clinical practice and patient expectations. Patients who have been through cancer treatment frequently experience scans as a form of active protection, a way of staying ahead of the disease. The evidence suggests that in certain cancers, earlier detection of recurrence does not reliably alter the final outcome, a conclusion that the field has been slow to integrate into surveillance protocols.

There is also the cumulative radiation exposure involved in repeated CT imaging over the years of follow-up. Each individual scan may appear to carry a low risk in isolation. Over a decade of quarterly or biannual imaging, the cumulative ionizing radiation dose is a figure that warrants more explicit discussion than most patients receive. The reassurance produced by frequent scanning may, in some cases, carry its own biological cost.

Here’s the full video

The Korea Thyroid Screening Example

The South Korean national thyroid cancer screening initiative that began in the 1990s produced one of the most instructive case studies in modern oncology on the difference between detecting more disease and improving more outcomes. Thyroid cancer diagnoses increased by approximately fifteenfold over the following two decades as ultrasound screening identified nodules and small cancers across a large population. Hospitals treated dramatically increased caseloads. Thyroid cancer incidence statistics showed what appeared to be an epidemic.

The death rate from thyroid cancer remained almost unchanged throughout the entire period.

The implication is straightforward and uncomfortable. A significant proportion of the cancers identified and treated during that initiative were clinically insignificant lesions that would never have progressed to cause symptoms or threaten life. The patients who underwent surgery, experienced complications, and in some cases faced lifelong thyroid hormone replacement had cancers that, left undetected, would have remained biologically irrelevant. The screening program produced diagnoses, treatments, and complications without producing a commensurate reduction in mortality.

This is not an argument against screening in general. It is a specific demonstration that detection volume and clinical benefit are not the same measurement, and that conflating them produces confident conclusions that the mortality data do not support.

The False Comfort Problem

The emotional trajectory that follows a cancer diagnosis and its treatment creates specific vulnerabilities that are rarely addressed in clinical follow-up. During active treatment, patients are typically vigilant, compliant, and focused on the disease’s biological reality. When treatment ends, and scans come back clear, the vigilance tends to relax. Lifestyle habits that were temporarily prioritized, exercise, dietary change, stress management, and weight control, often recede as the urgency of the diagnosis fades and normal life reasserts itself.

Dr. Petteruti has been direct on this point: the body’s internal environment does not become irrelevant after a scan returns clear. Inflammation, metabolic dysfunction, obesity, sedentary behavior, and chronic stress are established contributors to cancer biology, and their management after treatment ends carries genuine relevance to long-term outcomes. A survivor who returns to the same metabolic conditions that existed before diagnosis, reassured by a clean scan, is not necessarily protected by that reassurance in the way they believe they are.

The false comfort problem also appears in the way patients interpret follow-up care itself. A routine appointment in which the physician reviews scan results and reports no new findings can produce a sense of closure that the biology does not warrant. The appointment confirms what the imaging found. It does not confirm that the patient’s daily habits, nutritional status, inflammatory markers, or hormonal environment are supporting long-term recovery. Those questions require a different conversation, one that most surveillance appointments are not structured to have.

The Mammogram Debate as a Case Study in Balanced Communication

Few areas of cancer screening illustrate the communication problem more clearly than mammography. The consistent public health message has been that routine annual mammography saves lives through early detection, and the emotional weight of that message has made it genuinely difficult to examine the evidence with the nuance it deserves.

Several large studies examining mammography outcomes have found that routine screening detects cancers earlier without producing a statistically significant reduction in breast cancer mortality in certain populations. The harm side of that calculation includes false positives that lead to additional imaging, biopsies, extended periods of anxiety, and, in some cases, treatment for lesions that may never have become clinically significant. The cumulative radiation exposure from decades of annual mammograms in women who begin screening early adds a further dimension that receives minimal attention in standard screening promotion.

This does not mean mammography has no value. It means the evidence is more complicated than the uniform confidence with which the screening is promoted, and that women deserve access to that complexity when making decisions about their own care. The alternatives, breast MRI and ultrasound, are not equivalent to mammography in all clinical contexts, but they exist and are not radiation-based, and their relevance to individual patients is rarely discussed unless the patient raises the question herself.

Dr. Petteruti has examined the mammography evidence in detail, including what the studies actually show about survival benefit and what the false positive rate means in practice for real patients.

What Responsible Post-Treatment Health Looks Like

The alternative to false comfort is not anxiety. It is a structured, evidence-informed approach to long-term health that treats the years after cancer treatment as a period requiring active engagement rather than passive reassurance. The variables that influence cancer biology, metabolic health, body composition, inflammatory burden, sleep quality, and stress regulation do not become irrelevant after a scan returns clear. They become, if anything, more relevant because the patient now has a specific reason to take them seriously and the opportunity to act on them while the window for influence remains open.

Supplements occupy a legitimate but frequently misrepresented role in this conversation. Neither the reflexive dismissal of nutritional support nor the uncritical enthusiasm for unvalidated protocols serves patients well. The honest position is that specific nutritional deficiencies and metabolic conditions are addressable, that some compounds have genuine supporting evidence in specific contexts, and that this area deserves the same rigorous evaluation applied to any other clinical intervention.

The phrase “cancer-free” describes a scan result. It does not describe a biological state, a guarantee, or a reason to stop thinking carefully about the conditions that influence long-term health.

At Intellectual Medicine, Dr. Petteruti’s position has consistently been that informed patients make better decisions than reassured patients, and that the information required for genuine informed decision-making is available, even when the standard clinical appointment does not deliver it.

The Bottom Line

The standard pathway from an elevated PSA through biopsy, surgery, and radiation is built around a reasonable clinical goal. Physicians want to identify and treat cancers that are likely to cause harm, and when that harm is genuinely probable, that pathway serves patients well. What it does not always make transparent is that a significant proportion of prostate cancers grow slowly, remain confined to the gland for years or decades, and never develop into the kind of disease that shortens life or produces symptoms. The treatments applied to those cancers carry permanent consequences for bladder control, sexual function, hormonal health, and overall quality of life that do not disappear when the treatment ends.

The research supports intervention when the cancer is clearly aggressive, when clinical indicators point to a meaningful risk of progression, or when the expected benefit of treatment is strong enough to justify its use. The research does not support the position that every abnormal PSA reading or positive biopsy result demands immediate surgery or radiation. Those are different clinical situations, and treating them with the same urgency produces outcomes that the evidence does not endorse.

The wiser path is to examine the full picture before committing to any irreversible step. PSA trends over time, MRI findings, biopsy grade and volume, overall metabolic health, age, and the patient’s own priorities all belong in that evaluation. For many men, taking more time, gathering more information, and deferring intervention while monitoring carefully is not avoidance. It is a deliberate, evidence-based decision made by someone who understands what the data actually shows.

Subscribe now

What To Do With This Information

Before agreeing to a biopsy, surgery, or radiation, these questions deserve clear answers from your physician.

• Will this treatment clearly improve my chances of living longer, and by how much?

• What are the realistic effects on bladder control and sexual function, and how likely are they?

• What is the probability that my cancer will progress meaningfully if I choose active monitoring instead?

• How will this treatment affect my daily functioning, energy, and quality of life during and after?

• Am I making this decision based on the clinical evidence in front of me, or on the anxiety the diagnosis has produced?

If those questions do not have clear, specific answers, you do not yet have enough information to make a final decision. That is not a failure of the process. It is the process working correctly, because the goal is a decision that reflects your actual clinical situation rather than the momentum of a system that moves quickly and explains incompletely.

Dr. Petteruti has built the clinical philosophy at Intellectual Medicine around exactly this kind of deliberate, evidence-led engagement with cancer decisions. The podcast episodes listed throughout this post are a useful starting point for anyone who wants the full picture before walking into a urology appointment that may move faster than the evidence warrants.

If You Want To Go Deeper

If this topic matters to you, there are deeper conversations around it that explore how these decisions are made in real clinical settings. Dr. Petteruti discusses this in detail, including how long-term studies shape treatment choices and what they actually reveal about outcomes.

There are also extended notes and resources that break this down further, along with ongoing discussions around lifestyle, recovery, and long-term health decisions.

👉 Join here: https://tinyurl.com/DrPetterutiMember

You can also explore the broader framework behind this approach in Fight Cancer Like a Man, where these ideas are explained in more detail.

👉 https://tinyurl.com/FightLikeAManBook

Thanks for reading! Subscribe for free to receive new posts and support my work.

By the time many women reach their forties, the recommendation feels less like a suggestion and more like a routine expectation. Very few people stop to ask how much this screening test has actually been shown to change long-term outcomes.

(In this podcast, Dr Petteruti explains everything you MUST know about a biopsy:

The reasoning appears sound. If breast cancer is found earlier, treatment can begin sooner, and more lives can be saved. This idea has shaped breast cancer screening for decades and helped build a mammography industry worth billions of dollars each year. Yet a practice can become widely accepted long before most patients understand both its benefits and its limitations.

A closer review of the evidence tells a more complicated story. Mammograms can detect abnormalities before they can be felt, but they can also lead to false positives, repeated imaging, needle biopsies, and months of anxiety.

Several major studies have raised serious questions about how much routine screening changes the number of women who ultimately die from breast cancer. These findings do not mean mammograms are useless, but they do show that the conversation deserves more nuance than most women receive.

This leaves us with an important question. Do routine mammograms improve survival enough to justify the stress, radiation exposure, and follow-up procedures they often trigger? Or are many women entering a chain of medical decisions before they have been given balanced information?

The Promise of Early Detection

The belief that early detection saves lives is deeply rooted in medicine. In many situations, this principle is valid. Finding a dangerous condition before symptoms appear can create a larger window for treatment. That idea has guided screening programs for generations.

Mammography was built on this same assumption. A mammogram can reveal small changes in breast tissue long before a lump can be felt. This capability is often presented as clear proof that screening improves outcomes. The message is reassuring and easy to accept.

The more difficult question is whether finding cancer earlier always changes what happens over time. Some breast cancers are aggressive and spread quickly regardless of when they are found. Others grow so slowly that they may never become life-threatening. These differences are what make screening more complex than many women are led to believe.

The most meaningful measure is not how many cancers are detected. The central issue is whether screening reduces the number of women who die from the disease. Detecting more abnormalities is not automatically the same as saving more lives. This distinction changes how the evidence should be interpreted.

The Study That Challenged Everything

One of the most important screening trials was the Canadian National Breast Screening Study. This large study followed more than 80,000 women over many years. Researchers compared women who received routine mammograms with women who did not undergo regular screening. The purpose was to determine whether mammography reduced deaths from breast cancer.

The expectation was clear. If routine mammograms were dramatically improving survival, the screened group should show fewer breast cancer deaths. This assumption had shaped public health recommendations for years. Many physicians expected the results to confirm what they had long believed.

After years of follow-up, the study reported no meaningful difference in breast cancer deaths between the two groups. Women in the screened group were more likely to be diagnosed with breast cancer, but they were not clearly more likely to live longer. This challenged one of the most widely accepted assumptions in women’s health.

The study did not prove that mammograms have no role. What it showed is that the survival benefit may be smaller than many women have been led to believe. That distinction is important because screening is often presented as unquestionably life-saving. The evidence is more nuanced and deserves careful discussion.

Subscribe now

False Positives and the Emotional Cost of Screening

One of the most common results of screening is not a cancer diagnosis. It is uncertainty. A mammogram may reveal a shadow, a cluster of calcifications, or another finding that appears suspicious. The report may recommend more imaging or a needle biopsy.

For many women, this moment can be deeply unsettling. The possibility of cancer begins to shape every thought. Sleep becomes difficult, concentration suffers, and ordinary routines may feel overwhelming. Days or weeks can pass before additional testing provides an answer.

In many cases, the final result is benign. The abnormality was real, but it was not dangerous. This outcome is known as a false positive. Although no cancer is found, the emotional impact can be substantial.

Repeated imaging, waiting for results, and facing the possibility of a biopsy are part of the screening experience for many women. These consequences deserve as much attention as the potential benefits. Informed decisions require an honest understanding of what screening may lead to.

Radiation and a Reasonable Question

Mammography uses low-dose ionizing radiation to create images of breast tissue. The risk from a single study is generally considered small. However, screening is often repeated every year or every two years for decades. This means the exposure accumulates over time.

This raises a reasonable question. Why are we using radiation to examine an organ that is already vulnerable to cancer when other imaging methods are available? This question does not prove that mammograms cause breast cancer. It highlights the need to weigh even small risks against the expected benefits.

Radiation exposure is cumulative by nature. Each test adds to the total amount a woman receives over her lifetime. For some women, the risk may appear acceptable. Others may prefer to consider alternatives that do not rely on ionizing radiation.

The most important point is informed consent. Women deserve to know what the test involves and what trade-offs come with repeated exposure. That knowledge allows them to make decisions that fit their own priorities.

Why Ultrasound Gets Less Attention

Breast ultrasound uses sound waves rather than radiation. It is widely used to examine specific findings and can be especially useful in women with dense breast tissue. In these cases, mammograms may be more difficult to interpret. Ultrasound can provide additional information without exposing tissue to X-rays.

Many women also find ultrasound more comfortable because it does not require the same degree of compression. This leads to an understandable question. If ultrasound avoids radiation and may be helpful in many situations, why is it not discussed more often?

The answer involves more than medicine alone. Screening systems are built around established guidelines, insurance policies, and long-standing practice patterns. Once a standard pathway is in place, alternatives may receive less attention.

This does not mean ultrasound should replace mammography for every woman. It means women deserve to know that more than one option exists. When patients understand that alternatives are available, the conversation becomes more balanced.

When Insurance Shapes the Decision

Many people assume that if a test is covered by insurance, it must be the best option. That assumption feels natural, but it is not always accurate.

Insurance coverage is based on policy decisions, billing structures, and standardized rules. These systems are designed for administrative efficiency rather than individualized care.

A woman who prefers ultrasound may learn that her insurer will not cover it unless she first undergoes a mammogram. In that moment, a financial rule begins to shape what appears to be a medical decision. The covered option starts to feel like the only reasonable path.

This does not mean insurance companies are deciding what is best for every woman. It does mean administrative systems can make one approach seem automatic while alternatives become more difficult to access. Recognizing this distinction helps patients ask better questions.

Coverage decisions are important, but they are not medical truths. Women should understand that insurance rules reflect policy choices, not personal recommendations. That awareness creates more room for thoughtful decision-making.

The Biopsy Decision

When imaging identifies a suspicious area, the next recommendation is often a needle biopsy. The purpose is clear. A small sample of tissue is removed and examined under a microscope to determine whether cancer cells are present. This information can guide future treatment decisions.

A biopsy is a common procedure, but it is not a neutral event. It can cause pain, bleeding, bruising, infection, and emotional distress. For many women, the hardest part is not the physical discomfort but the fear that accompanies the procedure and the wait for results.

Some physicians and researchers have raised concerns about whether needle procedures could displace cells into nearby tissue. The clinical significance of this possibility remains uncertain. This does not prove that biopsies spread cancer, but it does show that uncertainty still exists.

The most important principle is informed consent. Women should understand why the biopsy is being recommended, what information it is expected to provide, and how that information will influence what happens next.

Coercion Disguised as Care

One of the most troubling features of modern medicine is how quickly a recommendation can begin to feel like a command. A woman may be told she is due for a mammogram or that an abnormal image requires a biopsy. The wording may be subtle, but the emotional effect can be powerful.

When fear enters the conversation, many patients feel they have no real choice. Some women report being told they are putting their lives at risk if they decline a procedure. Others describe feeling dismissed when they ask for more time or request a second opinion.

The body belongs to the patient. The physician’s role is to explain the evidence, discuss the uncertainties, and support thoughtful decision-making. Pressure has no place in informed consent.

Every woman has the right to pause, ask questions, and choose a different path. Medical recommendations are not commands. They are options that deserve careful consideration.

Subscribe now

Doctors Are Human

Most physicians are trying to help. They work within systems shaped by guidelines, liability concerns, insurance requirements, and limited appointment times. These forces can create a tendency to quickly follow established pathways.

That does not mean every recommendation is wrong. It does mean recommendations should be examined carefully, especially when they involve invasive or irreversible procedures. A physician’s confidence does not remove uncertainty from the underlying evidence.

The strongest doctor-patient relationships are built on open discussion rather than automatic compliance. A good physician welcomes questions and explains the reasoning behind a recommendation. An excellent physician gives patients enough time to think clearly.

Trust is important, but informed decisions require active participation. Women should feel comfortable asking direct questions and seeking second opinions when necessary. Thoughtful care depends on partnership, not pressure.

Self-Exams and Personal Awareness

One of the most practical tools in breast health costs nothing. A self-breast exam helps a woman become familiar with the normal feel and shape of her breasts. Over time, this awareness can make it easier to notice a meaningful change.

Self-exams do not require specialized equipment. They encourage women to stay engaged in their own health and to recognize what is normal for their bodies. If something unusual is detected, additional evaluation can then be considered.

A self-exam is not a guarantee that every abnormality will be found. It is a practical way to build familiarity and confidence. Many women find that this awareness provides reassurance and a greater sense of control.

The value of self-exams lies in personal awareness. Women who know their own bodies are better prepared to notice changes and decide when further investigation may be appropriate.

Dr. Petteruti’s Take

The most important principle in medicine is that the body belongs to the patient. No woman should feel rushed into a mammogram, biopsy, or any other procedure before she understands what the test has been shown to do, what it has not been shown to do, and what the possible downsides may be.

Screening can be useful, but usefulness does not remove the need for judgment. Ultrasound, MRI, and regular self-monitoring may be reasonable options depending on a woman’s risk factors, breast density, and personal preferences.

The strongest decisions are rarely made under pressure. They are made when fear is replaced with understanding. Time to think is often one of the most valuable parts of medical care.

Women should never feel guilty for asking questions. A thoughtful decision is not a delayed decision. It is a decision grounded in clarity and confidence.

The Bottom Line

Mammograms have been promoted for decades as one of the most important tools in women’s health. The research presents a more nuanced picture. Routine screening can detect abnormalities earlier, but it can also lead to false positives, repeated imaging, biopsies, radiation exposure, and significant anxiety.

Several major studies have questioned whether these tests produce the large survival benefits many women assume they do. This does not mean mammograms should never be used. It means the decision deserves the same careful thought as any other medical choice.

Women differ in age, family history, breast density, and personal priorities. A one-size-fits-all recommendation does not reflect that reality. Balanced information allows each woman to choose what aligns with her own comfort level and health goals.

The most defensible approach is to review the evidence, consider the possible trade-offs, discuss alternatives, and make a decision based on understanding rather than pressure. That is what informed consent should look like.

There are also extended notes and resources that break this down further, along with ongoing discussions around lifestyle, recovery, and long-term health decisions.

👉 Join here: https://tinyurl.com/DrPetterutiMember

You can also explore the broader framework behind this approach in Fight Cancer Like a Man, where these ideas are explained in more detail.

👉 https://tinyurl.com/FightLikeAManBook

Thanks for reading! Subscribe for free to receive new posts and support my work.

That message sounds reasonable. It has shaped prostate cancer care for many years. A rising PSA leads to a biopsy. A biopsy finds cancer cells. Cancer leads to surgery, radiation, or hormone treatment. Each step seems logical, and many men are told this is the safest path.

A closer look tells a more complicated story. That is a topic that experts like Dr Petteruti have discussed extensively.

(Watch this to discover more)

Many prostate cancers grow so slowly that they never cause serious harm. On the other hand, the treatments can cause lasting changes in bladder control, sexual function, strength, bone health, and daily life.

This leaves us with an important question: Do prostate biopsies, surgery, and radiation help most men live longer, or are some men going through irreversible treatments before the research clearly shows they need them?

The Biopsy Question

A prostate biopsy is a common procedure. In the United States, doctors perform about one million of them every year. During the procedure, a needle enters the prostate several times to remove small pieces of tissue. Those samples are examined under a microscope to look for cancer cells.

The purpose of a biopsy is to show whether cancer cells are present and how abnormal they look. This information can help guide treatment decisions.

What is often discussed less clearly is that a biopsy has real risks. It can cause bleeding, infection, pelvic soreness, and urinary problems. Just as important, a biopsy only shows that cancer cells are present. It does not tell whether those cells will ever cause symptoms or shorten your life.

Another question remains unanswered. During the biopsy, some prostate cells enter the bloodstream and lymph system. Doctors know this happens. What they do not know with certainty is whether it has any long-term effect. This does not prove the biopsy causes harm, but it does mean the issue has not been fully settled.

That’s why some oncologists believe biopsy should not be the first option or even be gotten at all.

(Here’s the full video)

This point deserves careful wording. The absence of proof of harm is not the same as proof of safety. Many men are told there is nothing to worry about. A more honest answer is that some questions remain open.

For some men, a biopsy is the right next step. A rising PSA, a suspicious MRI, and other risk factors may make tissue sampling useful. In those cases, the information gained may help clarify what should happen next.

For other men, time may provide the same clarity without an immediate procedure. Repeat PSA testing, MRI scans, and close follow-up can reveal whether the situation is stable or changing. In some cases, that added information leads to a better decision.

Early Diagnosis and the Meaning of Cure

Most people have heard that finding cancer early saves lives. In many cases, this is true.

Prostate cancer is different in one important way. Studies of men who died from unrelated causes have found that many had small prostate cancers they never knew about. These cancers remained quiet for years and never caused symptoms.

Finding cancer does not always mean treatment is needed.

That distinction is easy to miss. Once men hear the word cancer, many assume removing or destroying the prostate is the safest choice.

The research tells a more careful story. Long-term studies show that many men with low-risk prostate cancer live just as long whether they choose immediate treatment or careful monitoring.

In other words, removing the cancer cells is not always the same as helping a man live longer.

This does not mean treatment is useless. Some prostate cancers are aggressive and can spread if they are left untreated. In those situations, surgery, radiation, or drug therapy may provide a clear benefit.

The challenge is knowing which cancers are dangerous and which are likely to remain quiet. That is where good judgment becomes more important than fear. The goal is to match the treatment to the true level of risk.

A Closer Look at Prostate Removal

The da Vinci robotic system is one of the most well-known tools used to remove the prostate. Hospitals often present it as a major advance because it allows surgeons to operate with great precision.

The technology is impressive. But the most important issue is not how the prostate is removed.

But then, there is a question of whether the prostate needs to be removed at all.

Robotic surgery still removes the entire gland. Once it is gone, it cannot be restored. Studies have not shown dramatic differences in the outcomes men care about most, including bladder control and sexual function.

The machine may be advanced. The decision remains the same.

This is an important point because technology can create a false sense of certainty. When a procedure is presented with sophisticated equipment, many patients assume the outcome will be clearly better.

Doctors like Dr Petteruti have warned patients not to be distracted by ‘prostate biopsy frenzy’.

(Here’s the full podcast)

The reality is more limited. The nerves and muscles around the prostate are delicate. Even in expert hands, surgery can change how a man urinates, how he functions sexually, and how he feels about his body.

The question worth asking is: If surgery does not clearly improve survival in my case, is removing an organ the best first step?

The Side Effects That Deserve Equal Attention

Treatment discussions often focus on cancer control and survival. The effects on daily life may receive less attention, even though they can be severe.

Surgery can lead to urinary leakage, erectile dysfunction, loss of fertility, and changes in sexual function.

Radiation can cause burning with urination, bowel irritation, rectal bleeding, and sexual problems.

Hormone treatment can cause loss of sex drive, muscle loss, bone thinning, fatigue, weight gain, and a higher risk of heart disease.

These side effects are not rare. They are well-known consequences of treatment.

For some men, these trade-offs are worth it. For others, the treatment may cause major changes while offering only a small benefit.

Quality of life is not a minor issue. It affects sleep, relationships, self-confidence, physical ability, and independence. A treatment that extends life by a small amount may still feel unacceptable if the day-to-day cost is too high.

This is why the side effects deserve the same attention as the survival statistics. A decision cannot be complete unless both are discussed openly.

The Power of Saying No

(You might find this Dr Petteruti podcast helpful)

Many men do not realize they can say no, or at least not yet.

A doctor may recommend a biopsy, surgery, or radiation. That recommendation deserves respect, but it does not require immediate agreement.

Choosing to pause is not the same as ignoring the problem. It means taking the time to understand the likely benefits, possible harms, and alternatives.

That pause may include repeating the PSA test, obtaining an MRI, reviewing older records, improving overall health, or seeking a second opinion.

In many cases, time is not the enemy. Time allows the pattern to become clearer.

The power of saying no is that it returns control to the patient. Irreversible treatments can still be considered later if they are clearly needed. Until then, careful observation may provide the same information with fewer consequences.

What the Research Does and Does Not Show

Major studies, including the PIVOT and ProtecT trials, have helped answer an important question.

Do all men with localized prostate cancer benefit from immediate treatment?

The answer is no.

These studies show that men with aggressive cancer may benefit from surgery or radiation. They also show that many men with low-risk disease have a very low chance of dying from prostate cancer, even when they choose active surveillance.

This is one of the most important findings in modern prostate cancer care.

The research supports a tailored approach.

It does not support the idea that every diagnosis requires immediate treatment.

It also does not support making decisions based only on the word cancer. The details matter. PSA trends, Gleason score, MRI findings, age, overall health, and personal priorities all influence what is reasonable.

When these factors are considered together, the decision often becomes less urgent and more precise.

Tracking Outcomes Honestly

The best question in medicine is not what sounds promising. The best question is what actually happens over time.

Did treatment help men live longer?

How did it affect bladder control and sexual function?

What happened to energy, bone strength, heart health, and independence?

These are the outcomes that matter.

Many men with prostate cancer are more likely to die from heart disease than from the cancer itself. This does not minimize the diagnosis. It simply places it in a larger health context.

The most useful treatment plan is one that considers the whole body rather than a single organ.

Dr. Petteruti’s Take

Living longer is important. Living well is equally important.

Bladder control, sexual health, energy, strength, heart health, and independence are part of what life looks like after treatment. They should be discussed as carefully as survival statistics.

When a biopsy, surgery, or radiation is recommended, the most important question is whether the expected benefit is large enough to justify the changes that may follow.

The best decisions are rarely made in fear. They are made after the facts are clear and the trade-offs are understood.

The Bottom Line

The usual path from elevated PSA to biopsy, surgery, and radiation is based on a reasonable goal. Doctors want to find and treat cancers that are likely to cause harm.

What this process does not always make clear is that many prostate cancers grow slowly. Many never become dangerous. The treatments used to address them can permanently change the body.

The research supports treatment when the cancer is clearly aggressive or when the expected benefit is strong.

The research does not show that every abnormal PSA or positive biopsy means you need surgery or radiation right away.

The wiser approach is to look at the whole picture. PSA trends, MRI findings, biopsy results, overall health, and personal priorities all deserve attention. For many men, taking more time is not avoidance. It is a careful and evidence-based decision.

What To Do With This Information

Before agreeing to a biopsy, surgery, or radiation, ask these questions:

Will this treatment clearly help me live longer?

What are the likely effects on bladder control and sexual function?

What are the chances my cancer will grow if I choose monitoring?

How will this treatment affect my daily life?

Am I making this decision based on facts rather than fear?

If these questions do not have clear answers, you may need more information before making a final decision.

There are also extended notes and resources that break this down further, along with ongoing discussions around lifestyle, recovery, and long-term health decisions.

👉 Join here: https://tinyurl.com/DrPetterutiMember

You can also explore the broader framework behind this approach in Fight Cancer Like a Man, where these ideas are explained in more detail.

👉 https://tinyurl.com/FightLikeAManBook

Thanks for reading! Subscribe for free to receive new posts and support my work.

One conversation in a doctor’s office can make it feel as though time has suddenly become limited. Plans that once felt certain begin to feel fragile. Many men hear the diagnosis and immediately ask themselves one question: Am I going to die from this?

In many cases, the answer is no.

Prostate cancer is often very different from what most people imagine. Many forms grow slowly, remain confined to the prostate, and never become the main threat to a man’s life. Some men live for decades after diagnosis. Others die from causes completely unrelated to prostate cancer.

That reality is one of the most important themes Dr. Petteruti returns to on the Intellectual Medicine podcast.

A diagnosis may create urgency in the mind, but it does not always create urgency in the body.

Understanding that distinction can change the way every decision is made.

Why Many Men With Prostate Cancer Never Die From It

One of the most misunderstood facts about prostate cancer is that many men never die from the disease.

This is not a comforting phrase meant to reduce fear. It is what long-term research has shown. When prostate cancer is detected before it spreads, outcomes are often excellent. Many men continue to work, exercise, travel, and enjoy normal life for years after diagnosis.

Some prostate cancers are aggressive and require active treatment. Many others grow so slowly that they may never cause symptoms or shorten life expectancy. In these cases, the cancer may remain stable for years under careful monitoring.

This leads to one of Dr. Petteruti’s most important observations:

The biggest threat to quality of life is often not the cancer itself, but the treatment chosen too quickly.

That statement challenges what most people assume. Many believe that the safest response is to remove or destroy the cancer immediately. In reality, some treatments can cause urinary leakage, erectile dysfunction, fatigue, and other lasting effects, even when the cancer might never have become life-threatening.

This is why the first response to a diagnosis should be understanding, not panic.

The Question Dr. Petteruti Wants Every Man to Ask

Dr. Petteruti often frames the issue in a simple but powerful way.

Living longer is important (Watch Dr. Petteruti talk about men’s vitality here:

Living well is equally important.

Energy, physical strength, urinary control, sexual function, and independence are part of what life looks like after diagnosis. They should carry the same weight as survival when treatment decisions are made.

Before agreeing to any treatment, he encourages men to ask one clear question:

What is the evidence that this treatment will meaningfully improve my outcome, and what are the documented effects on quality of life?

That question changes the tone of the conversation.

It moves the discussion away from fear and toward evidence. It also reminds patients that treatment should be judged by two standards:

• How much it is expected to improve survival

• How it is likely to affect the life you want to continue living

When both sides are considered, the decision becomes far more thoughtful.

Five Factors That Influence Life Expectancy With Prostate Cancer

Life expectancy with prostate cancer depends on much more than the diagnosis itself. Several factors shape how the disease is likely to behave and what kind of approach is most appropriate.

1. How Aggressive the Cancer Appears

Some prostate cancers grow slowly and remain stable for years. Others have features that suggest a greater chance of progression. The biological behavior of the cancer often provides the clearest indication of how it may affect long-term survival.

2. Whether the Cancer Has Spread

Cancer that remains confined to the prostate generally carries a much better outlook than cancer that has spread to other areas of the body. Early detection creates more options and often leads to better outcomes.

3. Your Age and Overall Health

A man’s general health can be as important as the cancer itself. In some cases, heart disease, diabetes, or other chronic conditions have a greater influence on life expectancy than the prostate cancer diagnosis.

4. The Management Strategy Chosen

Some men benefit from surgery or radiation. Others are well served by active surveillance. The right approach depends on the biology of the cancer and the individual’s priorities.

5. How Closely the Condition Is Monitored

Regular follow-up helps detect meaningful changes early and provides time to adjust the strategy if needed. Careful monitoring often turns uncertainty into a well-managed long-term condition.

The Controversial Insight Most Men Need to Hear

One of the most difficult ideas for newly diagnosed men to accept is that immediate treatment is not always the best decision.

This does not mean doing nothing.

It means recognizing that some prostate cancers can be monitored safely while preserving urinary function, sexual health, and daily independence.

That approach can feel uncomfortable at first. Many men worry that waiting means taking an unnecessary risk.

Dr. Petteruti sees it differently.

When the evidence shows that a cancer is unlikely to cause harm in the near term, time becomes an advantage rather than a danger. It creates space to gather information, ask better questions, and avoid treatment that may not be needed.

In this context, patience is not neglect. It is a deliberate medical strategy.

Can You Live a Long Life With Prostate Cancer?

Yes, many men live a long life with prostate cancer (watch the full podcast here

Around 80 out of every 100 men diagnosed with prostate cancer survive for 10 years or more. When the cancer is identified before it spreads, the outlook is often even better. For many men, the disease becomes something they monitor and manage rather than a condition that defines or shortens their lives.

The most important factor is understanding the nature of your specific diagnosis. Some cancers require treatment. Others allow time for careful observation and thoughtful decision-making.

A diagnosis does not determine your future on its own.

The decisions made after diagnosis, and the clarity behind those decisions, often have the greatest influence on both longevity and quality of life.

How to Protect Quality of Life After a Diagnosis

Quality of life can change long before life expectancy does.

Many men survive prostate cancer for years, but some spend those years dealing with urinary leakage, erectile dysfunction, fatigue, and reduced independence. This is why the most important question is not only how long a treatment may help you live, but how it may affect the way you live.

Before agreeing to any treatment, ask:

1. How much is this treatment expected to improve my outcome?

2. What is the risk to urinary control?

3. What is the risk to sexual function?

4. Is careful monitoring a reasonable option?

5. How will this affect my energy, strength, and independence?

The strongest treatment plan is the one that protects both survival and the life you want to continue living.

A Different Way to Think About the Diagnosis

A prostate cancer diagnosis can make it feel as though your options are disappearing.

In many cases, the opposite is true.

An early diagnosis often provides time, information, and several reasonable paths to consider. That time can be used to understand the evidence, weigh the trade-offs, and choose a strategy that fits both your medical needs and your personal priorities.

The most important decisions are rarely the fastest ones.

Final Thoughts

A prostate cancer diagnosis does not automatically mean your life will be cut short. Many men live long, active, and meaningful lives after diagnosis, and some never experience serious complications from the disease itself.

The most important step is to replace fear with clarity. When you understand how the cancer is behaving and what each option is likely to change, you are in a far better position to protect both your longevity and the quality of the years ahead.

If You Want To Go Deeper

If this topic matters to you, there are deeper conversations around it that explore how these decisions are made in real clinical settings. Dr. Petteruti discusses this in detail, including how long-term studies shape treatment choices and what they actually reveal about outcomes.

There are also extended notes and resources that break this down further, along with ongoing discussions around lifestyle, recovery, and long-term health decisions.

👉 Join here: https://tinyurl.com/DrPetterutiMember

You can also explore the broader framework behind this approach in Fight Cancer Like a Man, where these ideas are explained in more detail.

👉 https://tinyurl.com/FightLikeAManBook

Thanks for reading! Subscribe for free to receive new posts and support my work.

That is not a criticism of urologists. It is an observation about how clinical momentum works, and why it does not always serve the patient standing in the middle of it.

A prostate biopsy is a real medical procedure with real consequences, and a man considering one deserves a complete account of what it involves, what it can and cannot tell him, and whether the evidence genuinely supports doing it now rather than pursuing other options first.

Dr Petteruti is of the opinion that NO MAN SHOULD BIOPSY HIS PROSTATE WITHOUT KNOWING THE RISK!

Watch the full podcast here

What the Procedure Actually Involves

The standard approach is a transrectal ultrasound-guided biopsy. A probe is inserted into the rectum to generate images of the prostate, and a spring-loaded needle extracts between 10 and 14 tissue cores from different regions of the gland.

Local anesthesia is administered beforehand, the procedure takes roughly 20 minutes, and most men return home the same morning. That is the version of events that tends to be communicated in clinical settings, and while it is accurate, it leaves out the part of the story that actually shapes a man’s experience of this decision.

There are other side effects that might affect live quality.

Find more information on this podcast

Recovery runs its own timeline. Blood in the urine resolves within a few days for most men. Blood in the semen is a different matter entirely, persisting for six to twelve weeks in many cases, and considerably longer for some.

Pelvic soreness and urinary discomfort are common in the first week. Most men manage these without significant difficulty. Others find the recovery more intrusive than anything their physician prepared them for, which tends to produce a particular kind of frustration that comes from feeling under-informed at the moment it mattered.

Infection is the risk that warrants the most honest discussion. Roughly 1 to 3 percent of prostate biopsies result in post-procedure infection serious enough to require hospitalization, even when antibiotics have been prescribed beforehand.

Sepsis, though rare, can develop quickly in the days following the procedure. This is not a reason to refuse a biopsy that is clinically warranted. It is a reason to understand that the procedure carries genuine medical risk, and that the threshold for agreeing to it should reflect that.

The Detection Problem Doctors Don’t Explain Clearly

A prostate biopsy can find cancer that would never have harmed the man it was found in. Low-grade, slow-growing prostate cancer confined to the gland is, for a substantial number of men, a condition they will live alongside rather than be threatened by.

The biopsy identifies it.

And from that point forward, the psychological weight of a cancer diagnosis shapes decisions in ways that do not always align with the clinical reality of what was actually found.

This is what Dr. Petteruti has spoken about directly on the Intellectual Medicine podcast, and his position is grounded in a straightforward clinical observation: the harm in prostate cancer management often does not come from the cancer.

Click here for the full podcast (

It comes from treating a low-risk finding with the urgency that high-risk disease would warrant, and from the effects that aggressive treatment, surgery, radiation, hormone therapy, produces on urinary function, sexual health, and overall quality of life. Detection without context is not the same thing as clarity. In some cases, it produces the opposite.

What Should Happen Before the Biopsy Conversation

Multiparametric MRI has genuinely changed what responsible pre-biopsy evaluation can look like. It allows a physician to examine the prostate in considerable detail before a single needle is introduced, identifying whether a suspicious lesion is present and where it sits within the gland.

When a biopsy follows an MRI, it can be targeted precisely rather than distributed across the standard grid of 12 to 14 sampling sites.

For many men, MRI findings alone are sufficient to clarify that immediate biopsy is unnecessary. For others, they sharpen the case for one and make the procedure itself more informative.

PSA, on its own, is also a less definitive signal than it is often presented as being. A PSA level that has remained stable for several years tells a different clinical story than one that has risen sharply over 18 months. PSA density, which relates the PSA reading to the volume of the prostate gland, adds meaningful context.

Free PSA ratios offer further signal about what the elevation is likely to reflect. These are not advanced or experimental tools. They are standard elements of a thorough evaluation that, in the right clinical hands, can genuinely inform whether biopsy is appropriate right now or whether monitored observation is the more defensible path.

The Conversation Worth Having Before You Agree

If a biopsy has been recommended and you are trying to determine whether to proceed, there are specific questions that belong in your next appointment.

• Has your PSA been tracked over time, and what direction has it been moving?

• Has an MRI been considered as a step before tissue sampling?

• What would a positive result realistically mean for your treatment options given your age, your PSA level, and the likely grade of any cancer found?

• If a low-grade cancer is identified, is active surveillance a clinically reasonable response rather than immediate intervention?

A physician who engages those questions seriously is practicing medicine in a way that respects the patient’s role in the decision.

If the answer to any of them is that the biopsy needs to happen first and the other questions can wait, it is worth understanding why, and whether a second opinion would sharpen the picture before you commit to a procedure you cannot undo.

What This Is Really About

The goal of this piece is not to steer anyone away from a prostate biopsy that is genuinely indicated. For some men, it is the right step, and in those cases, having it is an act of good clinical judgment. The goal is to push back against the idea that agreeing quickly is the same as acting responsibly, and that asking for more time or more information before consenting to an invasive procedure is somehow a form of denial.

Dr. Petteruti’s view, and the view that shapes the clinical philosophy at Intellectual Medicine, is that living longer and living well are not separate concerns to be traded against each other. They require the same foundation: decisions made with enough evidence, enough context, and enough time to actually think.

A biopsy ordered before that foundation exists is not a shortcut to answers. It is a procedure that may produce findings requiring their own careful interpretation, in a man who was never fully prepared for what any of it would mean.

The Intellectual Medicine podcast has covered PSA interpretation, biopsy decision-making, and active surveillance in episodes worth listening to before your next urology appointment. That hour of preparation may be the most useful thing you do before you decide anything else.

Want to Go Deeper?

The full clinical show notes for this episode, including detailed explanations of biopsy risks, what pathology results actually mean, and how to decide whether a biopsy is necessary, are available inside the Dr. Petteruti Men’s Vitality Membership.

Along with the complete show note library, you will find a twice-monthly newsletter written personally by Dr. Petteruti, a recipe library, protocol resources, and a community of men navigating prostate health together.

If this topic matters to you, there are deeper conversations around it that explore how these decisions are made in real clinical settings. Dr. Petteruti discusses this in detail, including how long-term studies shape treatment choices and what they actually reveal about outcomes.

There are also extended notes and resources that break this down further, along with ongoing discussions around lifestyle, recovery, and long-term health decisions.

👉 Join here: https://tinyurl.com/DrPetterutiMember

You can also explore the broader framework behind this approach in Fight Cancer Like a Man, where these ideas are explained in more detail.

👉 https://tinyurl.com/FightLikeAManBook

Thanks for reading! Subscribe for free to receive new posts and support my work.

Subscribe now

A rising PSA can be unsettling because it is often associated with prostate cancer. Dr. Petteruti frequently points out that a higher PSA is not a diagnosis. It is a signal that something has changed and that the change needs to be interpreted carefully before any conclusions are made.

Watch the full podcast here:

PSA, or prostate-specific antigen, is a protein produced by the prostate gland. A blood test measures how much of this protein is circulating in the bloodstream, and the result appears as a single number. That number can rise or fall over time, which is why a single result rarely tells the full story.

Several common conditions can raise PSA, including:

• Natural enlargement of the prostate with age

• Inflammation or infection

• Recent ejaculation

• Vigorous exercise, especially cycling

• Urinary retention

• Prostate cancer

This is where many men become concerned. The number is higher, and the assumption is that treatment may be the next step. In a recent episode of the Intellectual Medicine podcast, Dr. Petteruti addressed this exact moment and offered a perspective that runs counter to what many people expect.

Watch the Podcast here:

A rising PSA is not a medical emergency.

That statement may seem surprising at first. Yet in most cases, there is time to slow down and understand what the result actually means before agreeing to any invasive procedure or treatment.

Why Doctors Usually Repeat the PSA Test

The first response to a rising PSA is often to repeat the test.

This may seem too simple, but it is one of the most important parts of the evaluation. PSA levels can fluctuate for reasons that have nothing to do with cancer. A second test helps determine whether the increase is temporary or persistent.

Studies have shown that a meaningful percentage of men with an elevated PSA have a lower or even normal result when the test is repeated.

Before the follow-up test, doctors may recommend avoiding:

• Ejaculation for at least 48 hours

• Vigorous exercise, such as cycling

• Activities that place pressure on the prostate

If the PSA remains elevated, the next step is to look at the broader pattern.

Join Membership

Why the Trend Matters More Than a Single Number

Dr. Petteruti often explains that doctors are less interested in one PSA value than in how the number behaves over time.

A PSA that rises once and then stabilizes is interpreted differently from one that continues to increase across several tests. A gradual change over many years may reflect the normal enlargement of the prostate. A sharper and persistent increase may require closer investigation.

The number itself is only one piece of the story.

The trend reveals how the prostate is behaving.

When Imaging Helps Clarify the Picture

Sometimes blood tests do not provide enough information to understand what is happening.

When this occurs, multiparametric MRI can provide a more detailed view of the prostate. This type of imaging can identify areas that may require further attention and can also show when there are no concerning findings.

This step often helps separate harmless changes from findings that deserve closer monitoring.

The Controversial Insight Dr. Petteruti Shares

One of Dr. Petteruti’s strongest messages is that the greatest threat to quality of life is often not the rising PSA itself, but the rush to act before the evidence is clear.

This idea can feel uncomfortable, especially when a blood test result suggests that something serious may be developing. Many men assume that the safest response is to move quickly into more testing, procedures, or treatment. In some situations, that approach is appropriate. In many others, the better decision is to slow down and first understand what the PSA is actually showing.

A rising PSA does not reveal the whole picture. It does not indicate whether the change is temporary, whether cancer is present, or whether treatment would improve the outcome. Acting too soon can expose men to urinary leakage, erectile dysfunction, fatigue, and other long-term effects before it is clear that those trade-offs are necessary.

Dr. Petteruti often emphasizes that time is frequently an advantage rather than a liability. When there is no evidence of an immediate threat, taking a measured approach allows doctors to repeat the test, examine the trend, and use imaging when needed. Patience, in this setting, is not neglect. It is a deliberate medical strategy designed to protect both survival and quality of life.

Watch the full podcast here:

What Doctors Are Actually Trying to Determine

When PSA rises, doctors are usually trying to answer a series of practical questions:

1. Is the increase temporary or persistent?

2. What does the PSA trend look like over time?

3. Could inflammation or another non-cancerous condition explain the change?

4. Does imaging show anything concerning?

5. Is there clear evidence that treatment is necessary?

Each step adds context. Each answer reduces uncertainty. By the time a recommendation is made, the decision should be based on a complete picture rather than a single laboratory result.

The Question Every Man Should Ask

Dr. Petteruti encourages men to ask one question before agreeing to any treatment:

What is the evidence that this recommendation will meaningfully improve my outcome, and what are the documented effects on quality of life?

This question may seem simple, but it changes the entire discussion. Instead of focusing only on what can be done, it shifts attention to what is likely to help and what trade-offs may come with that decision. It also encourages your physician to explain the reasoning behind the recommendation rather than assuming that immediate action is automatically the best choice.

The second half of the question is just as important as the first. Living longer is important, but living well deserves equal consideration. Urinary function, sexual health, energy, physical strength, and daily independence are all part of life after a diagnosis.

When these factors are discussed openly, you are in a stronger position to choose an approach that protects both survival and the quality of the years ahead.

If You Want To Go Deeper

If this topic matters to you, there are deeper conversations around it that explore how these decisions are made in real clinical settings. Dr. Petteruti discusses this in detail, including how long-term studies shape treatment choices and what they actually reveal about outcomes.

There are also extended notes and resources that break this down further, along with ongoing discussions around lifestyle, recovery, and long-term health decisions.

👉 Join here: https://tinyurl.com/DrPetterutiMember

You can also explore the broader framework behind this approach in Fight Cancer Like a Man, where these ideas are explained in more detail.

👉 https://tinyurl.com/FightLikeAManBook

Thanks for reading! Subscribe for free to receive new posts and support my work.

Most people don’t want to die, and when cancer enters the conversation, that instinct becomes immediate. A prostate cancer diagnosis has a way of shifting how a man thinks almost overnight. What was once a distant concern becomes urgent, and that urgency drives behavior. It explains why so many men turn quickly to supplements, looking for something that gives them a sense of control. The supplement market understands this moment well. It is built around it.

If this is your first time here — subscribe free below to get every new episode breakdown delivered to your inbox.

Subscribe now

The Problem With the Supplement Market

There are thousands of products claiming to support the prostate or slow cancer. Some of these compounds have real biological relevance. Others exist because demand is high and marketing can shape perception. The challenge is not that supplements exist. The challenge is that most people do not know how to evaluate them.

Start With the Right Target

Most strategies begin by focusing on the disease. A better approach starts with the person. Strength, energy, mental clarity, and immune resilience are not secondary concerns. They are the foundation. Any approach to prostate health that ignores vitality is incomplete. A treatment that weakens the body in the process is not a meaningful win, even if it changes a lab value. This is why many men begin exploring supplements. Not to chase a cure, but to support the body while navigating the condition.

Sulforaphane and Cellular Protection

Broccoli has been associated with lower cancer rates for years, and one of the compounds responsible for that interest is sulforaphane. Research has shown that sulforaphane can activate tumor-suppressor pathways inside cells. That makes it biologically relevant. Some men increase their intake through diet, while others use concentrated forms to reach higher levels. The important point is not the form. It is understanding why the compound is being used in the first place.

DIM and the Role of Synergy

Diindolylmethane, or DIM, is another compound found in cruciferous vegetables. It has been linked to changes in cellular signaling that may be beneficial in prostate health. What matters here is not just DIM itself, but the concept it represents. Certain compounds may work more effectively together than they do alone. This idea of synergy has been used in medicine for a long time, but it is often lost in modern supplement use where people focus on single ingredients instead of systems.

Lycopene and Prostate Research

Lycopene, found in tomatoes, has also been studied in relation to prostate health. It carries antioxidant and anti-inflammatory properties, and higher levels in the body have been associated with lower prostate cancer mortality. That does not prove cause and effect, but it is enough to justify attention. Dietary sources can help, and supplements provide a more concentrated option for those who want to increase intake.

Free Radicals and Balance

As the body ages, free radical production increases. These unstable molecules can damage cells when they accumulate over time. This process, known as oxidative stress, is linked with many chronic conditions, including cancer. Antioxidants help balance this process, but the goal is not to eliminate free radicals entirely. It is to maintain equilibrium. This is where many people misunderstand supplementation. More is not always better. Balance is the objective.

Glutathione and NAC Support

Glutathione is one of the body’s most important antioxidants, playing a central role in detoxification and cellular protection. The challenge is that glutathione levels decline with age and stress. Rather than taking glutathione directly, many strategies focus on supporting the body’s ability to produce it. N-acetylcysteine, or NAC, provides a key building block. This approach works with the body instead of trying to override it.

Pomegranate and Practical Use

Pomegranate has gained attention for its role in prostate health, particularly in its potential to slow PSA progression. There is an important distinction here. Pomegranate juice contains high amounts of sugar, which can contribute to metabolic stress. Pomegranate extract provides the active compounds without that burden. Understanding that difference changes how the supplement is used.

The Pattern Most People Miss

When you step back and look at all of this, the pattern becomes clear. Supplements can play a role, but only when used with intention. They are not cures. They are not replacements for understanding. They are tools. Their value depends entirely on how they are used and how well the person using them understands the system they are trying to support.

Watch the full episode here:

The Real Goal

The goal is not to chase supplements. The goal is to strengthen the body. Nutrition, movement, metabolic health, sleep, and stress all influence how the body manages abnormal cells. Supplements can support that foundation, but they cannot replace it. When used correctly, they contribute to balance. When misunderstood, they add noise.

The Bottom Line

There is a lot of noise in this space. The advantage comes from knowing what matters and why.

I get asked regularly which supplements I actually use in clinical practice and how I think about formulating them. Rather than answer that question individually, I put together a formulation that reflects the framework I cover in this series.

You can find it here: Dr. Petteruti Prostate Vitality Supplement

Want to go deeper?

The full clinical show notes for this episode including the long-term trial data, research references, and a practical guide to the questions worth asking before any biopsy decision are inside the Dr. Petteruti Men’s Vitality Membership.

You will also find the complete recipe library, digital downloads, protocol resources, and Dr. Petteruti’s twice monthly newsletter written specifically for men navigating prostate health. Join for only $9.99 a month.

Join Membership

Every year hundreds of thousands of men hear the words prostate cancer and walk out of their urologist’s office headed toward surgery or radiation — often without being told that the studies behind those recommendations are weaker than they have been led to believe.

Dr. Stephen Petteruti spent two decades researching a different path. Fight Cancer Like a Man is the result — a straight-talking, evidence-based guide to prostate cancer management that prioritizes vitality, quality of life, and strategic containment over fear-driven intervention.

Inside you will find the science behind PSA monitoring, why biopsies carry risks most doctors don’t discuss, what repurposed medications like Metformin, Doxycycline, and Low-Dose Naltrexone actually do at the cellular level, and how to build a daily protocol that works with your body instead of against it.

If you or someone you love is navigating a prostate cancer diagnosis or simply wants to stay ahead of one, this book was written for you. Available on Amazon.

Get the Book

Intellectual Medicine is a reader-supported publication. To receive new posts and support my work, consider becoming a free subscriber.

Subscribe now

Dr. Stephen Petteruti is a board-certified physician specializing in longevity-focused, integrative medicine. He works with men navigating prostate cancer, testosterone and hormone health, aging, and performance using proactive, evidence-informed strategies grounded in real clinical practice.

Learn more at www.intellectualmedicine.com and www.drstephenpetteruti.com

Follow Dr. Petteruti on Instagram and Facebook: @intellectualmedicine

The content in this article reflects the opinions and clinical experience of Dr. Stephen Petteruti and is intended for informational and educational purposes only. It is not medical advice and should not replace guidance from your personal healthcare provider. Always consult your physician before making changes to your health regimen.

Hundreds of products claiming to support prostate health.
Detox protocols. Antioxidants. “Cancer-fighting” blends.

It all sounds promising.

And that’s exactly the problem.

A diagnosis creates uncertainty. Uncertainty creates urgency. And urgency makes people vulnerable to anything that sounds like help.

The supplement industry understands this.

Some of what’s being offered has real biological reasoning behind it. Some of it is driven almost entirely by demand and marketing. The difference matters.

Because not everything that sounds helpful is.

If this is your first time here — subscribe free below to get every new episode breakdown delivered to your inbox.

Subscribe now

Why Supplements Enter the Conversation

To understand where supplements fit, you have to understand what they’re trying to influence.

Two key processes come up repeatedly in cancer discussions:

Oxidative stress
Cellular metabolism

These are not fringe concepts. They are central to how cells function.

Free Radicals and Oxidative Stress

Free radicals are unstable molecules produced during normal processes like digestion and immune activity.

In small amounts, they serve a purpose.

In excess, they create damage.

They can disrupt:

• Cell membranes

• Proteins

• DNA

Over time, this type of damage accumulates. When it does, normal cellular function begins to break down. That environment can contribute to long-term disease processes, including cancer.

This is where antioxidants come in.

But the idea that more antioxidants automatically equals better outcomes is an oversimplification.

Cancer and Energy: The Warburg Effect

Cancer cells behave differently than normal cells.

Most healthy cells rely on oxygen-based energy production. Cancer cells often shift to a faster, less efficient pathway known as aerobic glycolysis.

This concept, described by Otto Warburg, helps explain how cancer cells fuel rapid growth.

It also raises an important question:

Can we influence that metabolic pathway?

That’s where certain supplements enter the discussion.

Alpha-Lipoic Acid: Targeting Cellular Energy

Alpha-lipoic acid is produced naturally in the body and acts as an antioxidant.

But its role may extend beyond that.

Some research suggests it may interfere with how cancer cells generate energy. If that pathway is disrupted, it can place stress on abnormal cells.

That does not make it a treatment.

But it does make it biologically relevant.

Melatonin: More Than Sleep

Most people think of melatonin as a sleep hormone.

That’s only part of the story.

Melatonin also interacts with the immune system. And the immune system plays a central role in identifying and managing abnormal cells.

There has been research looking at melatonin in men with advanced prostate cancer.

One study showed a significant difference in survival between men who used melatonin and those who did not.

That finding is interesting.

It is not definitive proof of cause.

But it is enough to justify attention.

Cancer Spread and Structural Breakdown

For cancer to spread, cells need to break free from their original structure.

This involves enzymes known as matrix metalloproteinases, or MMPs.

These enzymes weaken the structures that hold cells in place.

Once that structure is compromised, cells can move.

Understanding this process helps explain why certain compounds are studied for their ability to slow or interfere with that breakdown.

Pygeum Bark: Symptom Support vs Disease Impact

Pygeum bark has been used for years in men with urinary symptoms.

It can improve:

• Urinary flow

• Frequency

• Nighttime urination

There is also laboratory research exploring its effects on prostate cells.

But here’s the distinction that needs to be made clearly.

Improving urinary symptoms is not the same as treating cancer.

Those are two different conversations.

Stinging Nettle: Inflammation and Function

Stinging nettle root is another common ingredient in prostate supplements.

Its primary role is reducing inflammation.

Inflammation contributes to urinary symptoms, especially in men with prostate enlargement.

Reducing inflammation can improve function.

Again, that is useful.

But it is not the same as altering the course of cancer.

The Real Issue

Supplements are not the problem.

Misunderstanding them is.

Some have a role in supporting the body.
Some influence pathways worth paying attention to.
Some are harmless but overhyped.

And some, when used incorrectly or without context, can create harm.

The mistake is treating all of them as equal.

Or worse, treating them as a substitute for understanding what is actually happening in the body.

What This Really Comes Down To

The goal is not to chase supplements.

The goal is to understand the system.

Metabolism
Immune function
Inflammation
Cellular signaling

Supplements can play a role inside that framework.

They are not the framework.

Watch the full episode here:

The Bottom Line

There is no single supplement that solves prostate cancer.

There are compounds with biological relevance.
There are areas worth exploring.
There is also a large amount of noise.

Your job is not to react to that noise.

Your job is to understand what matters and why.

That’s where the real advantage is.

If you want a deeper breakdown of how these supplements fit into a broader clinical approach, including what to avoid and how to think about them strategically, I cover it in this episode.

More in Part 2.

Part 2 covers what I actually recommend, what I avoid, and how I think about formulation in clinical practice. If you want to see what that looks like before Part 2 publishes, it is here: Petteruti Prostate Vitality Supplement

Want to go deeper?

The full clinical show notes for this episode including the long-term trial data, research references, and a practical guide to the questions worth asking before any biopsy decision are inside the Dr. Petteruti Men’s Vitality Membership.

You will also find the complete recipe library, digital downloads, protocol resources, and Dr. Petteruti’s twice monthly newsletter written specifically for men navigating prostate health. Join for only $9.99 a month.

Join Membership

Every year hundreds of thousands of men hear the words prostate cancer and walk out of their urologist’s office headed toward surgery or radiation — often without being told that the studies behind those recommendations are weaker than they have been led to believe.

Dr. Stephen Petteruti spent two decades researching a different path. Fight Cancer Like a Man is the result — a straight-talking, evidence-based guide to prostate cancer management that prioritizes vitality, quality of life, and strategic containment over fear-driven intervention.

Inside you will find the science behind PSA monitoring, why biopsies carry risks most doctors don’t discuss, what repurposed medications like Metformin, Doxycycline, and Low-Dose Naltrexone actually do at the cellular level, and how to build a daily protocol that works with your body instead of against it.

If you or someone you love is navigating a prostate cancer diagnosis or simply wants to stay ahead of one, this book was written for you. Available on Amazon.

Get The Book

Intellectual Medicine is a reader-supported publication. To receive new posts and support my work, consider becoming a free subscriber.

Subscribe now

Dr. Stephen Petteruti is a board-certified physician specializing in longevity-focused, integrative medicine. He works with men navigating prostate cancer, testosterone and hormone health, aging, and performance using proactive, evidence-informed strategies grounded in real clinical practice.

Website: www.intellectualmedicine.com
Personal Website: www.drstephenpetteruti.com

Follow Dr. Petteruti on Instagram and Facebook: @intellectualmedicine

The content in this article reflects the opinions and clinical experience of Dr. Stephen Petteruti and is intended for informational and educational purposes only. It is not medical advice and should not replace guidance from your personal healthcare provider. Always consult your physician before making changes to your health regimen.

“Prostate cancer risk jumps sharply among men who skip PSA testing.”

It sounds urgent. It sounds like skipping the test is reckless. It sounds like you need to act right now.

But here is what that headline almost never tells you, the actual difference in prostate cancer deaths between men who screened and men who did not, when you look at the real numbers rather than the percentages, is far smaller than the headline implies.

That gap between what the data says and what the fear says is exactly what this episode is about.

If this is your first time here — subscribe free below to get every new episode breakdown delivered to your inbox.

Subscribe now

What This Episode Is About

PSA was never designed to diagnose cancer. It was designed to signal that something is worth looking at more closely. Levels rise because of inflammation, infection, prostate enlargement, exercise, and age — not just cancer. A higher number does not automatically mean something dangerous is happening.

Yet the standard pathway moves quickly. Elevated PSA leads to biopsy recommendation. Biopsy leads to a finding. Finding leads to treatment. All of it happening faster than most men have time to think clearly.

Dr. Petteruti slows that pathway down not to avoid necessary care but to make sure the care being recommended is actually necessary.

Three Things Worth Knowing

1. Medical statistics are designed to sound scarier than reality. Terms like “statistically significant” and “increased risk” sound alarming in a clinic room. They do not always translate into meaningful changes for one individual man. The question worth asking is not what the percentage says but what the absolute difference actually is and how it applies to your specific situation.

2. Long-term research does not always support rushing to surgery. The PIVOT study — published in the New England Journal of Medicine — followed men with localized prostate cancer for nearly twenty years. It found no significant difference in overall survival between men who had immediate surgery and men who chose careful observation. When survival looks similar between the two paths the side effects of treatment including incontinence and sexual dysfunction carry far more weight in the decision.

3. Many men die with prostate cancer rather than because of it. Autopsy studies have found incidental prostate cancer in approximately one in five men overall and in more than half of men over ninety, most of them small, low grade, and never causing symptoms during their lifetime. This does not mean ignoring the disease. It means not every finding demands immediate intervention.

Dr. Petteruti’s Take

Control belongs in your hands not in the momentum of a system that moves from PSA to biopsy to treatment before you have had time to ask a single question. Gathering information carefully, tracking PSA trends over time, using imaging before any invasive step, and working on the lifestyle factors that support overall health, that is a path that keeps you in the conversation rather than being swept along by fear.

What To Do With This Information

Before your next appointment ask your physician two specific questions.

First — what is my PSA trend over the past two to three years, not just today’s number?

Second — would a prostate MRI give us useful information before considering a biopsy?

If those questions are met with resistance that tells you something important about whether this physician is the right partner for your care.

Watch the full episode here:

Want to go deeper?

The full clinical show notes for this episode including the long-term trial data, research references, and a complete breakdown of how to interpret PSA results in context are inside the Dr. Petteruti Men’s Vitality Membership.

Along with the full show note library you will find a twice monthly newsletter written personally by Dr. Petteruti, a complete recipe library, protocol resources, and a community of men navigating prostate health together. Join for $9.99/month

Join Membership

And if you have not grabbed the book yet — Fight Cancer Like a Man is where the full clinical reasoning behind this approach lives in print.

Get The Book

Not subscribed yet? Every new episode breakdown lands in your inbox — free, always.

Subscribe now

Dr. Stephen Petteruti is a board-certified physician specializing in longevity-focused, integrative medicine. He works with men navigating prostate cancer, testosterone and hormone health, aging, and performance using proactive, evidence-informed strategies grounded in real clinical practice.

Learn more at www.intellectualmedicine.com and www.drstephenpetteruti.com

Follow Dr. Petteruti on Instagram and Facebook: @intellectualmedicine

The content in this article reflects the opinions and clinical experience of Dr. Stephen Petteruti and is intended for informational and educational purposes only. It is not medical advice and should not replace guidance from your personal healthcare provider. Always consult your physician before making changes to your health regimen.

How long do I have?

That fear is completely understandable. It is also, in many cases, not supported by the evidence.

If this is your first time here — subscribe free below to get every new episode breakdown delivered to your inbox.

Subscribe now

What This Episode Is About

Long-term research following men with prostate cancer for decades has produced a finding that most urologists do not lead with in the appointment room.

Many men diagnosed with prostate cancer do not die from it.

Heart disease, other cancers, and unrelated conditions are far more common causes of death in men who carry a prostate cancer diagnosis. The prostate cancer itself, particularly when it is low grade and slow growing is often remains stable for years while life continues normally around it.

This does not mean prostate cancer is never serious. It means the fear that drives most treatment decisions is frequently outrunning the evidence that should be guiding them.

Three Things Worth Knowing

1. Fear is one of the most powerful forces in medical decision making and one of the least reliable. When a man believes his life is in immediate danger he will accept almost any treatment offered. In prostate cancer that reaction often does not match what the data actually shows about how the disease progresses and who it ultimately harms.

2. Surgery and radiation do not always change the outcome. Studies comparing surgery, radiation, and careful monitoring over many years have found similar prostate cancer death rates across all three groups in men with low to intermediate risk disease. When survival looks comparable across treatment paths the side effects; incontinence, sexual dysfunction, fatigue, loss of strength become the most important variables in the decision. Not the cancer.

3. Over-treatment is a real and documented problem. Some prostate cancers grow so slowly they will never become life-threatening. Treating them aggressively produces real side effects without a clear survival benefit. This is not a fringe position, it is an emerging consensus among researchers who have been following the long-term trial data carefully.

Dr. Petteruti’s Take

Living longer matters. Living well matters just as much. Energy, strength, urinary function, sexual health, and daily independence are not secondary concerns. They are what the years after a diagnosis are actually made of. Any treatment decision that does not weigh both sides of that equation is an incomplete decision.

What To Do With This Information

If you or someone you love has received a prostate cancer diagnosis ask one question before agreeing to any treatment plan.

What is the evidence that this specific treatment will meaningfully change my outcome compared to careful monitoring and what are the documented effects on quality of life?

If your physician cannot answer that question clearly and specifically you do not yet have enough information to decide.

Watch the full episode here: 👉

Want to go deeper?

The full clinical show notes for this episode including the major long-term trials, what they reveal about prostate cancer mortality, and how Dr. Petteruti applies this evidence in clinical practice are inside the Dr. Petteruti Men’s Vitality Membership.

Along with the complete show note library you will find a twice monthly newsletter written personally by Dr. Petteruti, a recipe library, protocol resources, and a community of men navigating these decisions together. Join for $9.99/month

Join Membership

And if you have not grabbed the book — Fight Cancer Like a Man lays out the full framework behind everything Dr. Petteruti discusses on this podcast.

Get The Book

Not subscribed yet? Every new episode breakdown lands in your inbox — free, always.

Subscribe now

Dr. Stephen Petteruti is a board-certified physician specializing in longevity-focused, integrative medicine. He works with men navigating prostate cancer, testosterone and hormone health, aging, and performance using proactive, evidence-informed strategies grounded in real clinical practice.

Learn more at www.intellectualmedicine.com and www.drstephenpetteruti.com

Follow Dr. Petteruti on Instagram and Facebook: @intellectualmedicine

The content in this article reflects the opinions and clinical experience of Dr. Stephen Petteruti and is intended for informational and educational purposes only. It is not medical advice and should not replace guidance from your personal healthcare provider. Always consult your physician before making changes to your health regimen.